# 1|2024 Ceranews to the Point

**HEALTH ECONOMICS & POLICY** 

**OUTCOMES RESEARCH** 

**IMPLANT MATERIAL** 



# SUPPLEMENT REGISTRIES



## EDITORIAL

### **Registries 2023 in Review**



Dr. Alessandro Alan Porporati Director Medical and Scientific Affairs CeramTec GmbH, Germany

Dear Readers,

I am happy to share with you this new edition of the CeraNews supplement dedicated to arthroprosthetic registries, in which, as in previous editions, we gather trends on the use of articular bearings from the "real world" of total hip arthroplasty.

Not surprisingly, we focus on the use and performance of ceramic materials for hip replacements as documented by seven major national arthroplasty registries: NJR, AOA NJRR, EPRD, AJRR, NZJR, SAR, and LROI.

Readers' feedback has been extremely generous since we started, so we are thrilled to hear your feedback on this CeraNews registry supplement issue and hope that our readers will enjoy this 2024 edition as well. The previous editions have met with considerable success, and so we try each year to improve and offer new data as soon as the annual registry reports are publicly available. The lack of harmonization among registries still makes this task difficult, but we still strive year by year to improve it. I sincerely hope you enjoy it.

### **Fixation**

Like every year, interesting new trends are caught or trends that were weak and are strengthening to significance.Indeed, the data from 2023 reveals an interesting shift towards hybrid fixation techniques across most registries. Notably, the NJR and NZJR now report hybrid fixation as the top choice for hip replacements, indicating a clear shift away from uncemented fixation. For the first time, hybrid fixation has overtaken uncemented methods in the NZJR, covering 45% of procedures. This trend signifies a growing preference for combining the best of both worlds to improve surgical outcomes.

#### **Ceramic Femoral Heads: The New Standard**

Ceramic femoral heads confirm their popularity, becoming the preferred choice in many regions. According to the 2023 data, 54.2% of all total hip replacements (THRs) in the NJR, 90.4% in the EPRD, 27% in the SAR, and 75.9% in the LROI utilized ceramic femoral heads. The AJRR reports a cumulative usage rate of 81.4% from 2012 to 2022, reflecting a 3.4% increase from 2021. This growing adoption underscores the clinical trust in ceramic materials, known for their durability and superior performance.

2 | 52

Published by CeramTec GmbH CeramTec-Platz 1–9 | 73207 Plochingen, Germany Phone: +49 7153 611-513 ceranews@ceramtec.de | www.ceranews.com Stuttgart district court commercial register, no. 734826

VAT identification no. DE814031115

Responsible Editor: Dr. Henrich Mannel Concept and Editing: Florence Petkow, Dr. Alessandro Alan Porporati Design and Production: Fiona Lennartz

MD-IPM-00753 Version 1.0, August 2024

CeramTec is committed to selecting and bringing to interested parties relevant articles on bioceramics related topics. The presented authors' views and opinions are solely those of the authors of these publications. It is the focus and intent of CeraNews that CeramTec presents and comments on the authors' views and opinions in a specific context. Such comments and editorials therefore solely express CeramTec's views and opinions and not necessarily those of the quoted authors.

All statements are provided for educational purposes. For product, safety, and risk information, always refer to the labeling of the legal manufacturer.

Conventional femoral BIOLOX® *delta* heads and inserts as well as BIOLOX®OPTION products are registered by CeramTec's customers. Products are not registered / available in all countries.

BIOLOX<sup>®</sup>delta, BIOLOX<sup>®</sup>OPTION, BIOLOX<sup>®</sup> and CeramTec are registered trademarks of the CeramTec Group, Germany. MatOrtho<sup>®</sup> and ReCerf<sup>®</sup> are trademarks of MatOrtho Limited. H<sup>®</sup> is a trademark of Embody Orthopaedic Limited.

©CeramTec GmbH 2024. All rights reserved.

### **Registries 2023 in Review**

Ceramic-on-Polyethylene (CoP) bearings has emerged as the most favored bearing option in the NJR, EPRD, AJRR, NZJR, and LROI. The shift towards CoP bearings is primarily at the expense of Metal-on-Polyethylene (MoP) and Ceramic-on-Ceramic (CoC) bearings despite excellent results in the registries for ceramic monobloc constructs. The preference for CoP highlights its excellent clinical outcomes it delivers.

### **Delta Ceramic-on-Ceramic Resurfacing**

The AOA NJRR documented 346 MatOrtho ReCerf® hip resurfacing, while the NJR reported 249 Embody Ltd. H1® hip resurfacing procedures. Early results are promising, with significantly lower revision rates for BIOLOX®*delta* Ceramic-on-Ceramic (CoC) resurfacing compared to Metal-on-Metal (MoM) resurfacing, particularly in the short term. These findings are a first indication that modern ceramics could redefine the standards of hip resurfacing.

### **Expanding Use of Dual Mobility Bearings**

Dual mobility bearings are gaining more users in both primary and revision hip arthroplasty procedures. The NJR is currently the only registry reporting the use of ceramic heads within dual mobility constructs, with 41% of these implants featuring ceramic heads in primary procedures.

While we keep observing these advancements, it's crucial to address ongoing challenges. Infection remains the leading cause of revision surgeries in both Australia (23.3%) and the United States (22.5%), highlighting the need for enhanced infection control protocols. Aseptic loosening, dislocation, and periprosthetic fractures continue to be significant concerns, requiring continuous innovation and vigilance.

Today's popularity of ceramic materials in hip arthroplasty, introduced in the 1970s by pioneers such as Prof. Boutin and Prof. Mittelmeier, is the evidence of the power of innovation and evidence-based practice. As we now anticipate the publication of the 2024 hip registries starting after this summer, we at CeramTec remain committed to advancing orthopaedic care for the benefit of healthcare systems and patient outcomes.

### Happy Reading

Dr. Alessandro Alan Porporati Director Scientific and Medical Affairs CeraNews Editorial Team

3 | 52

Published by CeramTec GmbH CeramTec-Platz 1–9 | 73207 Plochingen, Germany Phone: +49 7153 611-513 ceranews@ceramtec.de | www.ceranews.com Stuttgart district court commercial register, no. 734826

VAT identification no. DE814031115

Responsible Editor: Dr. Henrich Mannel Concept and Editing: Florence Petkow, Dr. Alessandro Alan Porporati Design and Production: Fiona Lennartz

MD-IPM-00753 Version 1.0, August 2024

Ceram Lec is committed to selecting and bringing to interested parties relevant articles on bioceramics related topics. The presented authors' views and opinions are solely those of the authors of these publications. It is the focus and intent of CeraNews that CeramTec presents and comments on the authors' views and opinions in a specific context. Such comments and editorials therefore solely express CeramTec's views and opinions and not necessarily those of the quoted authors.

All statements are provided for educational purposes. For product, safety, and risk information, always refer to the labeling of the legal manufacturer.

### Ceramic experts

Conventional femoral BIOLOX® *delta* heads and inserts as well as BIOLOX®OPTION products are registered by CeramTec's customers. Products are not registered / available in all countries.

BIOLOX<sup>®</sup>delta, BIOLOX<sup>®</sup>OPTION, BIOLOX<sup>®</sup> and CeramTec are registered trademarks of the CeramTec Group, Germany. MatOrtho<sup>®</sup> and ReCerf<sup>®</sup> are trademarks of MatOrtho Limited. H<sup>®</sup> is a trademark of Embody Orthopaedic Limited.

©CeramTec GmbH 2024. All rights reserved.

### in $\boxtimes \textcircled{}$

1 | 2024

### **Executive Summary**

This is the summary of the most relevant information about total hip arthroplasty procedures recorded from seven national arthroplasty registries (NJR, AOA NJRR, EPRD, AJRR, NZJR, SAR and LROI) and presented in the respective annual reports 2023. These seven registries have been chosen, because they have been defined to be the most relevant, in terms of number of procedures annually recorded and/or quality of the data collected and analysed.

**Fixation** - A trend toward hybrid fixation can be observed in all six national registries except the AJRR. The hybrid fixation is the most popular choice for hip replacement as recorded by the NJR and NZJR. This is the first year that hybrid fixation has overtaken uncemented fixation (45%) as the most used form of fixation in NZJR. When only considering femoral head diameter in THRs, 32mm femoral head is the most common head size according to the considered European registries and NZJR, whereas the AOA NJRR and AJRR report a larger usage of the 36mm heads. There is also a trend towards 36mm femoral heads reported by the NZJR, EPRD and AJRR.

**Ceramic** - According to annual data, 54.2% of all THRs registered in NJR, 90.4% in EPRD, 27% in SAR, and 75.9% in LROI were performed with ceramic femoral heads. This accounts for an increase of more than 3.2% in NJR, 1% in EPRD, and 3.1% in LROI compared to the usage rates in 2021. The AJRR reported a cumulative data of ceramic femoral heads usage (2012-2022) achieved to 81.4% in 2022, with an 3.4% of increase more than 2021. While SAR declined slightly from 27.2% in 2021 to 26.9% in 2022. The use of CoP bearings has generally increased in 2022. CoP has become the most preferred bearing option of THRs in the NJR, EPRD, AJRR, NZJR, and LROI. The increased use of CoP bearings is mainly on the expense of MoP and CoC bearings.

**Dual Mobility** - The use of dual mobility bearings has steadily increased over the years both in primary THRs and revision procedures. The NJR is currently the only registry reporting the use of ceramic heads within dual mobility constructs, and about 41% of the total dual mobilities implanted in a primary procedure in 2022 had a ceramic head. The NJR confirms that the CoPoM dual mobility bearings show lower revision trend than the MoPoM combinations, but with no statistical significance. 346 CoC hip resurfacing (MatOrtho ReCerf®) procedures have been documented by the AOA NJRR with a cumulative revision rate of 0.3% (0.0%, 2.1%) at 1 year, and at 3 years (0.3% (0.0%, 2.1%)), with only 1 revision of all 346 procedures, was lower than other MoM resurfacing. Revision rate of 249 CoC resurfacing procedures is recorded by the NJR for the first time in 2022, the early revision rate at 1 year for CoC resurfacing is lower compared to MoM resurfacing at 3 years (1.91% (0.71%, 5.11%) vs. 2.90% (2.74%, 3.06%)) and 5 years (1.91% (0.71%, 5.11%) vs. 5.06% (4.85%, 5.28%)).

**Revision** - As far as the most common reasons for revision are concerned, (aseptic) loosening, infection, dislocation and (periprosthetic) fractures top the list in varying order. Infection has become the most common reason of all revision procedures in Australia (23.3%) and the United States (22.5%, 2012-2022). Revision rates for infection in other registries have increased year on year.

Published by CeramTec GmbH CeramTec-Platz 1–9 | 73207 Plochingen, Germany Phone: +49 7153 611-513 ceranews@ceramtec.de | www.ceranews.com Stuttgart district cou<u>rt commercial register, no. 73482</u>0

Stuttgart district court commercial register, no. 734826 /AT identification no. DE814031115

Responsible Editor: Dr. Henrich Mannel Concept and Editing: Florence Petkow, Dr. Alessandro Alan Porporati Design and Production: Fiona Lennartz

MD-IPM-00753 Version 1.0, August 2024

Ceram lec is committee to selecting and bringing to interested parties relevant articles on bioceramics related topics. The presented authors' views and opinions are solely those of the authors of these publications. It is the focus and intent of CeraNews that CeramTec presents and comments on the authors' views and opinions in a specific context. Such comments and editorials therefore solely express CeramTec's views and opinions and not necessarily those of the quoted authors.

All statements are provided for educational purposes. For product, safety, and risk information, always refer to the labeling of the legal manufacturer.

Conventional femoral BIOLOX® *delta* heads and inserts as well as BIOLOX®OPTION products are registered by CeramTec's customers. Products are not registered / available in all countries.

BIOLOX<sup>®</sup>delta, BIOLOX<sup>®</sup>OPTION, BIOLOX<sup>®</sup> and CeramTec are registered trademarks of the CeramTec Group, Germany. MatOrtho<sup>®</sup> and ReCerf<sup>®</sup> are trademarks of MatOrtho Limited. H1<sup>®</sup> is a trademark of Embody Orthopaedic Limited.

©CeramTec GmbH 2024. All rights reserved

### **OUTCOMES RESEARCH | REGISTRIES ANNUAL REPORTS 2023 IN REVIEW**

According to the NJR, the revision rates for CoP bearings remain consistently low or equivalent to those of other bearings up to 18 years. Remarkably, the NJR shows that good results were obtained with CoC and CoP bearings in young patients. The AOA NJRR Annual Report 2023 shows a statistically significant lower rate of revision of CoXLPE in comparison with MoXLPE after 2 years (HR=0.77 (0.72, 0.82), p<0.001). According to the EPRD, CoC had a significantly lower revision rate over the entire period than the other bearings, with the exception of CohXLPE+Antioxidants. Regardless of the fixation method, the NZJR shows that the revision rate for CoC bearings is lower than that for CoP and MoP. The revision rate for CoP is also lower than that of MoP. LROI also shows that CoC had a significantly lower cumulative major revision rate compared to CoP and MoP at 10 years.

Published by CeramTec GmbH CeramTec-Platz 1–9 | 73207 Plochingen, Germany Phone: +49 7153 611-513 ceranews@ceramtec.de | www.ceranews.com Stuttgart district court commercial register, no. 734826 VAT identification no. DE814031115

Concept and Editing: Florence Petkow, Dr. Alessandro Alan Porporati Design and Production: Fiona Lennartz

CeramTec is committed to selecting and bringing to inter-ested parties relevant articles on bioceramics related topics. The presented authors' views and opinions are solely those of the authors of these publications. It is the focus and intent of CeraNews that CeramTec presents and comments on the authors' views and opinions in a specific context. Such comments and editorials therefore solely express CeramTec's views and opinions and not necessarily those of the quoted authors.

All statements are provided for educational purposes. For product, safety, and risk information, always refer to the labeling of the legal manufacturer.

5 | 52

Conventional femoral BIOLOX® delta heads and inserts as well as BIOLOX®OPTION products are registered by CeramTec's customers. Products are not registered / available in all countries



1 | 2024

### **General Information of National Joint Registries**

### Table 1: General information of national joint registries.

Evaluation of the data by CeramTec based on the demographic information provided by Annual Reports 2023 of NJR, AOA NJRR, EPRD, AJRR, NZJR, SAR, and LROI. 1,364 institutions submitting data to the AJRR from across all 50 states and the District of Columbia are recorded by end of 2022. \* Indicates single year data only generated in 2022.

	NJR	AOA NJRR	EPRD	AJRR	NZJR	SAR	LROI
Name	National Joint Registry	Australian Orthopaedic Association National Joint Replacement Registry	Endoprothe- senregister Deutschland	American Joint Replacement Registry	The New Zealand Joint Registry	Swedish Arthroplasty Register	Dutch Arthroplasty Register
Area Coverage	England, Wales, North- ern Ireland, the Isle of Man and Guernsey	Australia	Germany	United States <sup>1</sup>	New Zealand	Sweden	Netherlands
Participation	Mandatory	Mandatory	Voluntary (from 2025 Mandatory)	Voluntary	Voluntary	Mandatory	Mandatory
Completeness	approx. 100%	99%	70%		70%	approx. 98%	approx. 98%
Duration	2003-2022	1999-2022	2012-2022	2012-2022	1997-2022	2005-2022	2007-2022
Type of Joint	Hips, knees, ankles, elbows, and shoulders	Hips, knees, and shoulders	Hips and knees	Hips and knees	Hips, knees, ankles, elbows, and shoulders	Hips and knees	Hips, knees, ankles, shoulders, elbows, wrists, and fingers
Primary hip replacement procedures	1,448,541 (All resurfacing: 2.9%; THRs: 94.3%, 2003- 2022)	850,603 (THRs: 642,704, Resurfacing: 3.1%, 1999- 2022)	177,826 (THR: 88.1%, 2022)*	THRs: 1,014,772 (2012-2022) (Elective primary THRs)	THRs: 173,306 (1997-2022)	Total and Hemi HRs: 541,078 (1979-2022)	THRs: 423,773 (2007-2022)
Gender	Male 40.2%	Male 45.1%	Male* 41%		Male 46.3%	Male 42%	Male* 36%
	Female 59.8%	Female 54.9%	Female* 59%		Female 53.7%	Female 58%	Female* 64%
Mean age years (SD)	68.2 (11.4)	67.8 (11.5)	70*	65.7 (11.3)	Male 65.9	69	69.4 (10.5)*
					Female 68.6		

Published by CeramTec GmbH CeramTec-Platz 1–9 | 73207 Plochingen, Germany Phone: +49 7153 611-513 ceranews@ceramtec.de | www.ceranews.com Stuttgart district court commercial register, no. 734826 VAT identification no. DE814031115

Responsible Editor: Dr. Henrich Mannel Concept and Editing: Florence Petkow, Dr. Alessandro Alan Porporati Design and Production: Fiona Lennartz

CeramTec is committed to selecting and bringing to inter-ested parties relevant articles on bioceramics related topics. The presented authors' views and opinions are solely those of the authors of these publications. It is the focus and intent of CeraNews that CeramTec presents and comments on the authors' views and opinions in a specific context. Such comments and editorials therefore solely express CeramTec's views and opinions and not necessarily those of the quoted authors.

All statements are provided for educational purposes. For product, safety, and risk information, always refer to the labeling of the legal manufacturer.

6 | 52

Conventional femoral BIOLOX® *delta* heads and inserts as well as BIOLOX®OPTION products are registered by CeramTec's customers. Products are not registered / available in all countries.

#### Table 1: General information of national joint registries.

Evaluation of the data by CeramTec based on the demographic information provided by Annual Reports 2023 of NJR, AOA NJRR, EPRD, AJRR, NZJR, SAR, and LROI. <sup>1</sup> 1,364 institutions submitting data to the AJRR from across all 50 states and the District of Columbia are recorded by end of 2022.

\* Indicates single year data only generated in 2022.

	NJR	AOA NJRR	EPRD	AJRR	NZJR	SAR	LROI
Main Surgery Indication	Osteoarthritis (91.2%)	Osteoarthritis (88.2%)			Osteoarthritis (88.2%)	Osteoarthritis (93%)	Osteoarthritis (86.1%)*
ASA Score	ASA 1: 14.9% ASA 2: 67.7% ASA 3: 16.8% ASA 4: 0.6% ASA 5: <0.1%	ASA1:9%ASA2:52.4%ASA3:36.7%ASA4:2%ASA5:0	Mean ASA: 2.2%*			ASA 3-4 : 19.9%	ASA 1: 14%* ASA 2: 60%* ASA 3-5: 26%*
BMI (kg/m²)		Underweight: 1.1% Normal: 22.1% Pre-Obese: 36.6% Obese Class 1: 24.8% Obese Class 2: 10.4% Obese Class 3: 5.1%	Mean BMI: 27.2*		Mean BMI: 29.13 (5.73)	Mean BMI: 27.3	Mean BMI: 27.2 (4.6)*
Survival Rate	Cumulative Revision (95% Cl): 8.17% (7.99%-8.35%) at 19-year	Revision burden in 2022 is 7.3% (lowest burden yet). Cumulative Revision (95% Cl): 11.5% (11.2%-11.7%) at 20 years	Cumulative Revision of elective hip replacements with uncemented stem fixation (95% Cl): 4.3% (4.2%-4.5%) at 8-year Cumulative Revision of elective hip replacements with cemented stem fixation (95% Cl): 4.1% (3.8%-4.3%) at 8-year		85.60% at 20-year	Revision rate decreased to 9.8% in the period 2020– 2022	Cumulative Revision of THRs (95% Cl): 6.02% (5.88%- 6.16%) at 14-year
Total number of primary hip joint replacements in 2021	99,043 (All resurfacing: 0.7% THRs: 98%)	THRs: 42,923	177,826 (THR: 88.1%, 2022)*		THRs: 9,207	18,339 primary elective hip replacements	THRs: 36,707

Published by CeramTec GmbH CeramTec-Platz 1–9 | 73207 Plochingen, Germany Phone: +49 7153 611-513 ceranews@ceramtec.de | www.ceranews.com Stuttgart district court commercial register, no. 734826 VAT identification no. DE814031115

Responsible Editor: Dr. Henrich Mannel Concept and Editing: Florence Petkow, Dr. Alessandro Alan Porporati Design and Production: Fiona Lennartz

CeramTec is committed to selecting and bringing to inter-ested parties relevant articles on bioceramics related topics. The presented authors' views and opinions are solely those of the authors of these publications. It is the focus and intent of CeraNews that CeramTec presents and comments on the authors' views and opinions in a specific context. Such comments and editorials therefore solely express CeramTec's views and opinions and not necessarily those of the quoted authors.

All statements are provided for educational purposes. For product, safety, and risk information, always refer to the labeling of the legal manufacturer.

Conventional femoral BIOLOX®delta heads and inserts as well as BIOLOX®OPTION products are registered by CeramTec's customers. Products are not registered / available in all countries.

in 🖂 🌐

### Demographics

### Total Hip Replacements (THRs) by Fixation

Apart from the AJRR's classification of fixation methods into uncemented fixation stem group and cement fixation stem group, a clear overall trend towards hybrid fixation can be observed in all six identified national registries.

In Australia, Germany, the United States, and the Netherlands, uncemented fixation is still the most commonly used method. In Sweden, the use of cemented fixation decreased over the years, but still accounts for 52% of all THR procedures.

Hybrid fixation was documented to be utilized in 40.3%, 36.2%, and 51% by NJR, AOA NJRR and NZJR, respectively. Hybrid fixation is the most popular choice for hip replacement, according to the NJR and NZJR. This is the first year that hybrid fixation has replaced uncemented fixation as the most commonly used form of fixation in New Zealand.

### 😹 NJR

In 2022, 19.1% of primary hip replacements recorded in the NJR dataset were cemented fixation, 36.2% were uncemented fixation, and 40.3% were hybrid fixation. The use of cemented fixation in all hips has decreased by almost three times, from 53.5% in 2004 to 19.1% in 2022, while the percentage of uncemented fixation has increased from 18.3% in 2004 to a peak of 44.1% in 2012, then dropped to 36.2% in 2022. The usage of hybrid fixation has more than tripled, from 12.5% in 2004 to 40.3% in 2022.<sup>1</sup>

### 🛅 AOA NJRR

In Australia, there is a continuing trend for uncemented fixation to increase from 51.3% in 2003 to 61.9% in 2022. The percentage of hybrid fixation decreased slightly from 36.8% in 2020 to 36.2% in 2022, while the numbers for cemented fixation decreased significantly from 13.9% in 2003 to 1.9% in 2022. This trend stabilizes in 2022 compared to the situation in 2021.<sup>2</sup>

### EPRD

Uncemented fixation remains the most popular fixation modality, accounting for 77.2% of procedures. Hybrid fixation increased from 15.7% in 2016 to 17.5% in 2021, then to 17.9% in 2022, while cemented fixation accounted for 3.7% in 2022.<sup>3</sup>

### 

In the United States, uncemented femoral stem fixation remains clearly the preferred

8 | 52

Published by CeramTec GmbH CeramTec-Platz 1–9 | 73207 Plochingen, Germany Phone: +49 7153 611-513 ceranews@ceramtec.de | www.ceranews.com Stuttgart district court commercial register, no. 734826

Stuttgart district court commercial register, no. 734826 VAT identification no. DE814031115

Responsible Editor: Dr. Henrich Mannel Concept and Editing: Florence Petkow, Dr. Alessandro Alan Porporati Design and Production: Fiona Lennartz

MD-IPM-00753 Version 1.0, August 2024

CeramTec is committed to selecting and bringing to interested parties relevant articles on bioceramics related topics. The presented authors' views and opinions are solely those of the authors of these publications. It is the focus and intent of CeraNews that CeramTec presents and comments on the authors' views and opinions in a specific context. Such comments and editorials therefore solely express CeramTec's views and opinions and not necessarily those of the quoted authors.

All statements are provided for educational purposes. For product, safety, and risk information, always refer to the labeling of the legal manufacturer.

### Ceramic experts

Conventional femoral BIOLOX® *delta* heads and inserts as well as BIOLOX®OPTION products are registered by CeramTec's customers. Products are not registered / available in all countries.

BIOLOX<sup>®</sup>delta, BIOLOX<sup>®</sup>OPTION, BIOLOX<sup>®</sup> and CeramTec are registered trademarks of the CeramTec Group, Germany. MatOrtho<sup>®</sup> and ReCerf<sup>®</sup> are trademarks of MatOrtho Limited. HI<sup>®</sup> is a trademark of Embody Orthopaedic Limited.

©CeramTec GmbH 2024. All rights reserved.



(in) 🖂 🌐

option. It was used in 95.4% of all elective primary THR procedures in 2022. To note, 4.6% of femoral stems were cemented, which is lower than that in other international registries, and there was a significant increase in cemented fixation with advancing age (p<0.0001).4

### 🚵 NZJR

The usage of cemented hip replacement has fallen to about 4% in 2022. From 2010 to 2020, the use of hybrid fixation was on an upward trend, then decreasing slightly in 2021 and rising to 51% in 2022. This is the first year that hybrid fixation has overtaken uncemented fixation (45%) as the most commonly used form of fixation.<sup>5</sup>

#### SAR

Over the past 20 years, the use of cemented fixation has declined each year until 2020. The percentage of fully cemented fixation was 52% in 2021 and again in 2022. Cemented fixation is more commonly used in female patients. The registry still encourages cemented fixation for patients over 70 years old. The percentage of uncemented fixation is about 33% in 2022, occurring mainly in the under-75 age group. The proportion of hybrid prostheses raised from 7.1% in 2020 to 8% in 2021 then to about 9% in 2022.6

### **LROI**

In 2022, uncemented fixation remains the preferred method of fixation in the Netherlands, with a small and sustained increase in use from 62.8% in 2013 to 68.1% in 2022. The use of cemented fixation decreased slightly each year to 20.4% in 2022. The use of hybrid fixation is on an upward trend, from 4.6% in 2013 to 8.6% in 2022.7



Evaluation of the data by CeramTec is based on NJR Annual Report 2023 Page 54 Table 3.H2, AOA NJRR Ánnual Report 2023 Page 106 Figure HT3, EPRD Annual Report 2023 Page 30 Table 6, and LROI Annual Report 2023 Page 21 Figure Fixation. For the comparison of THR's fixation methods, unconfirmed data and all resurfacing data were excluded when analyzing datasets from the NJR and EPRD. The usage percentage of cemented, uncemented, hybrid and reverse hybrid fixations sum up to 100%

Evaluation of the data by CeramTec based on AJRR Annual Report 2023 Page 42 Figure 2.22

Published by CeramTec GmbH CeramTec-Platz 1–9 | 73207 Plochingen, Germany Phone: +49 7153 611-513 ceranews@ceramtec.de | www.ceranews.com Stuttgart district court commercial register, no. 734826

Figure 1a: Distribution of fixation methods in primary THRs in 2022 (Annual

Netherlands as well as

Figure 1b: Distribution

of femoral stem fixation

(2012-2022) in the USA.

methods in primary THRs

Guernsey.

England, Wales, Northern

Ireland, the Isle of Man and

Data): in Australia, Germany,

Concept and Editing: Florence Petkow, Dr. Alessandro Alan Porporati Design and Production: Fiona Lennartz

CeramTec is committed to selecting and bringing to inter-ested parties relevant articles on bioceramics related topics. The presented authors' views and opinions are solely those of the authors of these publications. It is the focus and intent of CeraNews that CeramTec presents and comments on the authors' views and opinions in a specific context. Such comments and editorials therefore solely express CeramTec's views and opinions and not necessarily those of the quoted authors

All statements are provided for educational purposes. For product, safety, and risk information, always refer to the labeling of the legal manufacturer.

9 | 52

Conventional femoral BIOLOX® *delta* heads and inserts as well as BIOLOX® OPTION products are registered by CeramTec's customers. Products are not registered / available in all

1|2024

### **OUTCOMES RESEARCH | REGISTRIES ANNUAL REPORTS 2023 IN REVIEW**

1 | 2024

(in) 🖂 🌐

### **THRs by Femoral Head Diameter**

When considering only femoral head diameters in THRs, the 32mm femoral head is the most commonly used femoral head size as reported by the European registries and NZJR, while the AOA NJRR and AJRR report a higher use of the 36mm femoral head. The EPRD, NZJR and AJRR also report a trend towards the use of 36mm femoral head.

The NJR and AOA NJRR Annual Report 2023 provide information on the size as well as the material of femoral heads used in THRs allowing for analysis of the combination. It should be mentioned that the AOA NJRR provides prosthesis-specific analysis regarding femoral head diameter restricted for modern prostheses, including mixed ceramic/mixed ceramic, and all femoral head materials (metal, ceramic, and ceramicised metal) used in combination with cross-linked polyethylene.

#### 😹 NJR

As in 2021, the most common head size recorded by NJR was 32mm, followed by 36mm and 28mm. According to Figure 3.H3 (e) in the Annual Report 2023, it can be observed that since 2003, there has been a transition from small head sizes (22.25mm and 26mm) in cemented hip replacements to large head sizes (>28mm) in uncemented or hybrid hip replacements can be observed since 2003. The NJR highlights that 32mm and 36mm CoP bearings are the main options for 2022.<sup>1</sup>

### 🛅 AOA NJRR

Among all non-XLPE bearings, femoral heads smaller than 32mm predominate. In the XLPE bearing group, the use of 32mm and >32mm femoral heads were about 2.5 times higher than that of small head sizes (<32mm), respectively. The Australian registry distinctly looks at the usage of "mixed ceramic" components (combination of alumina and zirconia) in THRs. During the period 2003-2022, 36-38mm mixed ceramic/mixed ceramic bearings accounted for approximately 73.6% of all primary THR procedures performed with this bearing surface in patients diagnosed for osteoarthritis.<sup>2</sup>

### EPRD

Utilization of the 32mm (47.8%) and 36mm (47.1%) heads is similar. The 32mm femoral heads have shown a downward trend in utilization, decreasing from 61.2% of all primary THRs in 2014 to 47.8% in 2022. In contrast, the use of 36mm femoral heads increased each year, from 31.4% in 2014 to 47.1% in 2022. The use of 28mm femoral heads has remained stable over the past five years, at approximately 5%.<sup>3</sup>

Published by CeramTec GmbH CeramTec-Platz 1–9 | 73207 Plochingen, Germany Phone: +49 7153 611-513 ceranews@ceramtec.de | www.ceranews.com Stuttgart district court commercial register, no. 734826

Stuttgart district court commercial register, no. /34826 VAT identification no. DE814031115

Responsible Editor: Dr. Henrich Mannel Concept and Editing: Florence Petkow, Dr. Alessandro Alan Porporati Design and Production: Fiona Lennartz

MD-IPM-00753 Version 1.0, August 2024

CeramTec is committed to selecting and bringing to interested parties relevant articles on bioceramics related topics. The presented authors' views and opinions are solely those of the authors of these publications. It is the focus and intent of CeraNews that CeramTec presents and comments on the authors' views and opinions in a specific context. Such comments and editorials therefore solely express CeramTec's views and opinions and not necessarily those of the quoted authors.

All statements are provided for educational purposes. For product, safety, and risk information, always refer to the labeling of the legal manufacturer. Cerant experts

Conventional femoral BIOLOX® *delta* heads and inserts as well as BIOLOX®OPTION products are registered by CeramTec's customers. Products are not registered / available in all countries.

BIOLOX<sup>®</sup>delta, BIOLOX<sup>®</sup>OPTION, BIOLOX<sup>®</sup> and CeramTec are registered trademarks of the CeramTec Group, Germany. MatOrtho<sup>®</sup> and ReCerf<sup>®</sup> are trademarks of MatOrtho Limited. H1<sup>®</sup> is a trademark of Embody Orthopaedic Limited.

©CeramTec GmbH 2024. All rights reserved

### (in) 🖂 🌐

1 | 2024

### AJRR

Since 2012, the share of 36mm heads in primary elective THRs has been on an upward trend, from 48.1% in 2012 to 62.9% in 2022, and has remained stable over the last five years. There is a corresponding decrease in the utilization of 32mm heads from 32.8% to 17.3% during this period. The volume of treatments with head sizes larger than 40mm grows slowly, from 5.5% in 2013 to 8.8% in 2022. Utilization of small heads (<28mm) remains relatively stable over time, with only 3,441 cases by 2022.4

### 📉 NZJR

Since 2017, New Zealand has shown a trend towards the use of 36mm heads, with 32mm remaining the most commonly used head size. 88% of procedures use a 36mm or 32mm head, 10% use a 28mm head, and approximately 2% use a >36mm head.<sup>5</sup>

### SAR

The 32mm head is the most commonly used head size, with a utilization rate of about 80% in 2022 (acc. to Figure 5.1.8 in the registry report). In contrast, the utilization of 36mm heads increases slightly in 2022, from 10% to 12.5% of all reported THRs in 2021.6

### **LROI**

In 2022, the most common head size in the Netherlands remains 32mm, with a utilization rate of 62%. 36mm head usage increases slightly, from 23.4% in 2020 to 27.1% in 2022. The small head size (22-28mm) shows a significant decrease in utilization from 30.7% in 2013 to 10.6% in 2022. The share of large head sizes (≥38mm) stabilizes at around 0.3%.<sup>7</sup>

**Distribution of Head Sizes in** Primary THRs in 2022 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% FPRD **I ROI** 

≤28mm 32mm 36mm ≥40mm

Evaluation of the data by CeramTec based on EPRD Annual Report 2023 Page 31 Table 12, and LROI Annual Report 2023 Page 23 Figure Femoral head diameter.

11 | 52

Published by CeramTec GmbH CeramTec-Platz 1–9 | 73207 Plochingen, Germany Phone: +49 7153 611-513 ceranews@ceramtec.de | www.ceranews.com Stuttgart district court commercial register, no. 734826

Figure 2a: Distribution of head sizes in primary THRs in 2022 (Annual Data): in Germany

and Netherlands.

Concept and Editing: Florence Petkow, Dr. Alessandro Alan Porporati Design and Production: Fiona Lennartz

ested parties relevant articles on bioceramics related topics. The presented authors' views and opinions are solely those of the authors of these publications. It is the focus and intent of CeraNews that CeramTec presents and comments on the authors' views and opinions in a specific context. Such comments and editorials therefore solely express CeramTec views and opinions and not necessarily those of the quoted

All statements are provided for educational purposes. For product, safety, and risk information, always refer to the labeling of the legal manufacturer.

Conventional femoral BIOLOX® *delta* heads and inserts as well as BIOLOX® OPTION products are registered by CeramTec's customers. Products are not registered / available in all

in 🖂

Figure 2b: Total Percentage of head sizes in primary THRs: in the United States and Netherlands.

INSIGHTS

Total Percentage of Head Sizes in Primary THRs



Evaluation of the data by CeramTec based on EPRD Annual Report 2023 Page 31 Table 12, and LROI Annual Report 2023 Page 23 Figure Femoral head diameter.

12 | 52

Published by CeramTec GmbH CeramTec-Platz 1–9 | 73207 Plochingen, Germany Phone: +49 7153 611-513 ceranews@ceramtec.de | www.ceranews.com Stuttgart district court commercial register, no. 734826 VAT identification no. DE814031115

Responsible Editor: Dr. Henrich Mannel Concept and Editing: Florence Petkow, Dr. Alessandro Alan Porporati Design and Production: Fiona Lennartz

CeramTec is committed to selecting and bringing to inter-ested parties relevant articles on bioceramics related topics. The presented authors' views and opinions are solely those of the authors of these publications. It is the focus and intent of CeraNews that CeramTec presents and comments on the authors' views and opinions in a specific context. Such comments and editorials therefore solely express CeramTec's views and opinions and not necessarily those of the quoted authors.

All statements are provided for educational purposes. For product, safety, and risk information, always refer to the labeling of the legal manufacturer.

Conventional femoral BIOLOX®*delta* heads and inserts as well as BIOLOX®OPTION products are registered by CeramTec's customers. Products are not registered / available in all

### (in) 🖂 🌐

### **Distribution of Femoral Heads by Material**

The following analysis focuses on primary THRs involving ceramic, metal, and ceramicised metal femoral heads, which are the most common femoral head materials used in THRs.

### **NJR**

Ceramic femoral heads continue to exceed metal femoral heads in utilization. Ceramic femoral heads are utilized in 54.2% of all primary THRs, compared to 51.9% in 2021. Correspondingly, the use of metal femoral heads decreased from 45.6% in 2021 to 43.1% in 2022.1

### 🛅 AOA NJRR

The use of ceramic heads has grown steadily over the past decade. Consequently, the registry has recorded a decline in the use of metal heads over the same period.<sup>2</sup>

#### EPRD

The trend toward ceramic femoral heads is still increasing, accounting for 90.4% of all primary THRs in 2022, with an increase from 89.5% in 2021.<sup>3</sup>

### 

In the United States, the percentage of ceramic femoral heads in THRs continues to increase from 38.4% in 2012 to 81.4% in 2022. In contrast, the AJRR reports a sustained decline in the use of CoCr femoral heads from 55.6% in 2012 to 8.4% in 2022, explaining that this trend is due to surgeons' concerns about trunnion and taper corrosion with CoCr femoral heads. The use of ceramicised metal heads nearly doubled in 2022 (10.2%) compared to 2012 (6.1%).<sup>4</sup>

### **MZJR**

According to the NZJR Annual Report 2023, the use of ceramic femoral heads has continued to increase since 2013. In 2017, the percentage of ceramic femoral heads used surpassed that of the metal femoral heads.<sup>5</sup>

### SAR

In Sweden, the use of ceramic femoral heads has continued to increase over the years, however, a very slight decrease (-0.3%) was recorded in 2022. Metal is still the most used femoral head material in hip procedures.<sup>6</sup>

### **LROI**

In the Netherlands, the use of ceramic femoral heads has been increasing since 2013, from 54.3% to 75.9% in 2022. Correspondingly, the use of metal femoral heads has

13 | 52

Published by Ceram Tec GmbH Ceram Tec-Platz 1–9 | 73207 Plochingen, Germany Phone: +49 7153 611-513 ceranews@ceramtec.de | www.ceranews.com Stuttgart district court commercial register, no. 734826

Concept and Editing: Florence Petkow, Dr. Alessandro Alan Porporati Design and Production: Fiona Lennartz

CeramTec is committed to selecting and bringing to inter-ested parties relevant articles on bioceramics related topics. The presented authors' views and opinions are solely those of the authors of these publications. It is the focus and intent of CeraNews that CeramTec presents and comments on the authors' views and opinions in a specific context. Such comments and editorials therefore solely express CeramTec's views and opinions and not necessarily those of the quoted authors

All statements are provided for educational purposes. For product, safety, and risk information, always refer to the labeling of the legal manufacturer.

Conventional femoral BIOLOX® *delta* heads and inserts as well as BIOLOX® OPTION products are registered by CeramTec's customers. Products are not registered / available in all

(in) 🖂 🌐

### **OUTCOMES RESEARCH | REGISTRIES ANNUAL REPORTS 2023 IN REVIEW**

decreased from 30.5% in 2013 to 16.6% in 2022. There is a slight upward trend in the use of ceramicized metal heads, from 5.7% in 2013 to 11.6% in 2020, but then decreasing to 7.6% in 2022.7



Evaluation of the data by CeramTec based on NJR Annual Report 2023 Page 54 Table 3.H2. The usage rates of ceramic and metal heads correspond to the sum of the usage rates of the bearings containing ceramic and metal heads, respectively. In order for the total number to be equal to the number of THRs, hip resurfacing and unconfirmed data were excluded from the percentage calculation.



### **Composition of Femoral Heads in Primary THRs by Year**

Evaluation of the data by CeramTec based on EPRD Annual Reports 2014 to 2023 (For operation year 2014, the number indicates percentage of all primary hip replacements. For operation years 2015 to 2021, the numbers indicate percentage of all primary THRs). The usage rates of ceramic, metal and ceramicised metal heads correspond to the sum of the usage rates of the bearings containing ceramic, metal and ceramicised heads, respectively.

Published by CeramTec GmbH CeramTec-Platz 1–9 | 73207 Plochingen, Germany Phone: +49 7153 611-513 ceranews@ceramtec.de | www.ceranews.com Stuttgart district court commercial register, no. 734826 VAT identification no. DE814031115

Concept and Editing: Florence Petkow, Dr. Alessandro Alan Porporati Design and Production: Fiona Lennartz

CeramTec is committed to selecting and bringing to inter-ested parties relevant articles on bioceramics related topics. The presented authors' views and opinions are solely those of the authors of these publications. It is the focus and intent of CeraNews that CeramTec presents and comments on the authors' views and opinions in a specific context. Such comments and editorials therefore solely express CeramTec's views and opinions and not necessarily those of the quoted authors

All statements are provided for educational purposes. For product, safety, and risk information, always refer to the labeling of the legal manufacturer.



14 | 52

Conventional femoral BIOLOX® *delta* heads and inserts as well as BIOLOX®OPTION products are registered by CeramTec's customers. Products are not registered / available in all countries

Figure 4: Composition of femoral heads in primary THRs by year in Germany.

femoral heads in primary THRs by year in England, Wales, Northern Ireland, the Isle of Man, and Guernsey.



INSIGHTS

### 1|2024

### **OUTCOMES RESEARCH | REGISTRIES ANNUAL REPORTS 2023 IN REVIEW**

in 🖂 🌐

Figure 5: Composition of femoral heads in primary THRs (2012-2022) in the United States.

Figure 6: Composition of femoral heads in primary

THRs by year in the Netherlands.

INSIGHTS



Evaluation of the data by CeramTec based on AJRR Annual report 2023 Page 38 Figure 2.16.



#### Evaluation of the data by CeramTec based on LROI Annual report 2023 Page 26 Figure Femoral head component. The usage rate of ceramic heads is equal to the percentage of Ceramics/Zo, the usage rate of metal heads is equal to the percentage of Cobalt chrome, the usage rate of Ceramicised Metal Heads is that of oxidized zirconium.

Published by CeramTec GmbH CeramTec-Platz 1–9 | 73207 Plochingen, Germany Phone: +49 7153 611-513 ceranews@ceramtec.de | www.ceranews.com Stuttgart district court commercial register, no. 734826 VAT identification no. DE814031115

Concept and Editing: Florence Petkow, Dr. Alessandro Alan Porporati Design and Production: Fiona Lennartz

CeramTec is committed to selecting and bringing to inter-ested parties relevant articles on bioceramics related topics. The presented authors' views and opinions are solely those of the authors of these publications. It is the focus and intent of CeraNews that CeramTec presents and comments on the authors' views and opinions in a specific context. Such comments and editorials therefore solely express CeramTec's views and opinions and not necessarily those of the quoted authors.

All statements are provided for educational purposes. For product, safety, and risk information, always refer to the labeling of the legal manufacturer.

Conventional femoral BIOLOX® *delta* heads and inserts as well as BIOLOX®OPTION products are registered by CeramTec's customers. Products are not registered / available in all

15 | 52

### in 🖂 🌐

1 | 2024

### **Bearing Surfaces**

CoP has become the most popular bearing option in THRs in most countries. When the analysis of bearing type is limited to CoP, MoP, CoC and CMoP only, the trend in use is as follows.

### 😹 NJR

CoP bearing utilization increases from 11.4% in 2004 to 47.5% in 2021, then to 50.4% in 2022 in England, Wales, Northern Ireland, the Isle of Man and Guernsey. Correspondingly, MoP bearings utilization declines from 78.9% in 2004 to 45.6% in 2021, then to 43.1% in 2022. According to the last annual report, CoC bearings were implanted in 3.8% of all primary THRs with a known bearing type. CoP was preferred for both uncemented and hybrid hips. As in the previous two years, hybrid CoP was the most commonly implanted construct in 2022, accounting for 23% of all primary hip replacements, followed by uncemented CoP (20.3%) and hybrid MoP (15.2%).<sup>1</sup>

#### 🛅 AOA NJRR

In Australia, almost the totality, 97.3%, of the bearings implanted in 2022 consisted of mixed ceramic- and metal-on-cross-linked polyethylene, and mixed ceramic-on-mixed ceramic, defined as "modern bearing surfaces" by the registry. The Australian registry distinctly looks at the usage of "mixed ceramic" components like BIOLOX®*delta*, vs. pure alumina ceramic in primary total conventional hip replacements. CoC with mixed ceramic consisted of 99.9% of all procedures with a CoC bearing. Referring to the polyethylene using in primary total conventional hip replacement, the proportion of XLPE was 97.5%. It can be observed that the use of XLPE + antioxidant increased 11.4% compared to that of 2021. The use of CoXLPE has increased during the last 10 years at the expense of CoC and MoXLPE.<sup>2</sup>

### 📕 EPRD

Utilization of CoP bearings continues to grow, from 67% in 2014 to 82.8% in 2022. Over the same time period, CoC bearings utilization declines from 15.4% to 7.5% and MoP bearings declines from 15.8% to 5.3%. CMoP femoral head utilization remains stable at 2.7% of all primary THRs in 2022.<sup>3</sup>

### AJRR

The use of CoP increased substantially from 33.2% in 2012 to 72.6% in 2022. During the same period, MoP declined down from 48.8% to 4.4%. The use of CMoP increased from 5.1% in 2012 to 7.7% in 2022.<sup>4</sup>

### 📉 NZJR

In New Zealand, the CoP bearing surface continues to increase while MoP decreases, with CoP and MoP use accounting for 91% of all procedures in 2022. CoC use increases 16 | 52

Published by CeramTec GmbH CeramTec-Platz 1–9 | 73207 Plochingen, Germany Phone: +49 7153 611-513 ceranews@ceramtec.de | www.ceranews.com Stuttgart district court commercial register, no. 734826

VAT identification no. DE814031115

Responsible Editor: Dr. Henrich Mannel Concept and Editing: Florence Petkow, Dr. Alessandro Alan Porporati Design and Production: Fiona Lennartz

MD-IPM-00753 Version 1.0, August 2024

CeramTec is committed to selecting and bringing to interested parties relevant articles on bioceramics related topics. The presented authors' views and opinions are solely those of the authors of these publications. It is the focus and intent of CeraNews that CeramTec presents and comments on the authors' views and opinions in a specific context. Such comments and editorials therefore solely express CeramTec's views and opinions and not necessarily those of the quoted authors.

All statements are provided for educational purposes. For product, safety, and risk information, always refer to the labeling of the legal manufacturer.

Conventional femoral BIOLOX® *delta* heads and inserts as well as BIOLOX®OPTION products are registered by CeramTec's customers. Products are not registered / available in all countries.

BIOLOX<sup>®</sup>delta, BIOLOX<sup>®</sup>OPTION, BIOLOX<sup>®</sup> and CeramTec are registered trademarks of the CeramTec Group, Germany. MatOrtho<sup>®</sup> and ReCerf<sup>®</sup> are trademarks of MatOrtho Limited. H1<sup>®</sup> is a trademark of Embody Orthopaedic Limited.

©CeramTec GmbH 2024, All rights reserved

(in) 🖂 🌐

slightly compared to 2021, accounting for 7% of total use.<sup>5</sup>

### SAR

The percentage of all primary THRs using CoP in 2022 remains unchanged compared to 2021, at approximately 27%. However, due to the increase in the total number of hip replacement procedures, the registry reports a slight increase in the absolute number of CoP articulation.6

### **LROI**

Among all primary THRs, the annual utilization rate of CoP increases from 54.3% in 2013 to 71.6% in 2022. Consequently, the use rate of MoP bearings decreases from 30.9% in 2013 to 15.7% in 2022. The utilization rate of CoC bearings decreases from 8.5% in 2013 to 4.6% in 2022.7



Evaluation of the data by CeramTec based on the NJR Annual Report 2023 Page 54 Table 3.H2. The usage rates of CoP, MoP and CoC correspond to the sum of the usage rates of CoP, MoP and CoC bearings with different fixation methods, respectively. In order for the total number to be equal to the number of THRs, hip resurfacing and unconfirmed data were excluded from the percentage calculation.

17 | 52

Conventional femoral BIOLOX® *delta* heads and inserts as well as BIOLOX® OPTION products are registered by CeramTec's customers. Products are not registered / available in all

Figure 7: Usage of CoP, MoP and CoC in primary THRs by year in England, Wales, Northern Ireland, the Isle of Man and Guernsey.

Published by CeramTec GmbH CeramTec-Platz 1–9 | 73207 Plochingen, Germany Phone: +49 7153 611-513 ceranews@ceramtec.de | www.ceranews.com Stuttgart district court commercial register, no. 734826

Concept and Editing: Florence Petkow, Dr. Alessandro Alan Porporati Design and Production: Fiona Lennartz

CeramTec is committed to selecting and bringing to inter-ested parties relevant articles on bioceramics related topics. The presented authors' views and opinions are solely those of the authors of these publications. It is the focus and intent of CeraNews that CeramTec presents and comments on the authors' views and opinions in a specific context. Such comments and editorials therefore solely express CeramTec's views and opinions and not necessarily those of the quoted authors.

All statements are provided for educational purposes. For product, safety, and risk information, always refer to the labeling of the legal manufacturer.

(in) 🖂

Figure 8: CoP, MoP, CoC and CMoP usage in primary THRs by year in Germany.

INSIGHTS



Evaluation of the data by CeramTec based on the EPRD Annual Reports 2014 to 2023 (For operation year 2014, the number indicates percentage of all primary hip replacements. For operation years 2015 to 2022, the numbers indicate percentage of all primary THRs). The usage rates of CoP, MoP and CMoP correspond to the sum of the usage rates of bearings containing ceramic, metal and ceramicised metal heads in conjunction with different polyethylene types, respectively.



CoP, MoP and CMoP Usage in Primary

Evaluation of the data by CeramTec based on the AJRR Annual report 2023 Page 39 Figure 2.18.

Figure 9: CoP, MoP and CMoP usage in primary THRs by year in the United States.

18 | 52

Published by CeramTec GmbH CeramTec-Platz 1–9 | 73207 Plochingen, Germany Phone: +49 7153 611-513 ceranews@ceramtec.de | www.ceranews.com Stuttgart district court commercial register, no. 734826 VAT identification no. DE814031115

Concept and Editing: Florence Petkow, Dr. Alessandro Alan Porporati Design and Production: Fiona Lennartz

CeramTec is committed to selecting and bringing to inter-ested parties relevant articles on bioceramics related topics. The presented authors' views and opinions are solely those of the authors of these publications. It is the focus and intent of CeraNews that CeramTec presents and comments on the authors' views and opinions in a specific context. Such comments and editorials therefore solely express CeramTec's views and opinions and not necessarily those of the quoted authors.

All statements are provided for educational purposes. For product, safety, and risk information, always refer to the labeling of the legal manufacturer.

Conventional femoral BIOLOX® *delta* heads and inserts as well as BIOLOX®OPTION products are registered by CeramTec's customers. Products are not registered / available in all countries

in 🖂 🌐

### **OUTCOMES RESEARCH | REGISTRIES ANNUAL REPORTS 2023 IN REVIEW**

Figure 10: CoP, MoP, CoC and CMoP usage in primary THRs by year in the Netherlands.

INSIGHTS



Evaluation of the data by CeramTec based on LROI Annual Reports 2023 Page 26 Figure Articulation.

19 | 52

Published by CeramTec GmbH CeramTec-Platz 1–9 | 73207 Plochingen, Germany Phone: +49 7153 611-513 ceranews@ceramtec.de | www.ceranews.com Stuttgart district court commercial register, no. 734826 VAT identification no. DE814031115

Responsible Editor: Dr. Henrich Mannel Concept and Editing: Florence Petkow, Dr. Alessandro Alan Porporati Design and Production: Fiona Lennartz

CeramTec is committed to selecting and bringing to inter-ested parties relevant articles on bioceramics related topics. The presented authors' views and opinions are solely those of the authors of these publications. It is the focus and intent of CeraNews that CeramTec presents and comments on the authors' views and opinions in a specific context. Such comments and editorials therefore solely express CeramTec's views and opinions and not necessarily those of the quoted authors.

All statements are provided for educational purposes. For product, safety, and risk information, always refer to the labeling of the legal manufacturer.

Conventional femoral BIOLOX®*delta* heads and inserts as well as BIOLOX®OPTION products are registered by CeramTec's customers. Products are not registered / available in all

### in 🖂 🌐

1 | 2024

### Dual Mobility (DM)

The usage of dual mobility bearings has steadily increased over the years. The data on dual mobility bearings are reported by registries including NJR, AOA NJRR, EPRD, AJRR, SAR and LROI.

#### 😹 NJR

Before 2013, dual mobility was rarely used. From 2014 to the present, the use of dual mobility has steadily increased, especially in hybrid fixation group. The use of dual mobility with a metal head and with a ceramic head account for 2.76% of all primary THRs, compared to 2.46% in 2021. The use of dual mobility with a metal head (MoPoM) increased from 1.54% in 2021 to 1.63% in 2022, while with a ceramic head (CoPoM) increased from 0.92% in 2021 to 1.12% in 2022.<sup>1</sup>

### 🛅 AOA NJRR

In Australia, the annual use of dual mobility constructs is increasing. Their use has increased by 7.6% since 2021. Compared to other acetabular prostheses, dual mobility implants are most commonly used for fractured neck of femur, tumor and failed internal fixation.<sup>2</sup>

### EPRD

EPRD included dual mobility bearing couples for the first time in its 2019 Annual Report analysis. In 2022, this implant type accounted for 1.9% of all bearings in primary THRs, the same as in 2021, while in acetabular revisions, dual-mobility cups were chosen in 38.5% of cases, increasing from 10% in 2014 to 38.5% in 2022.<sup>3</sup>

### AJRR

In the United States, the use of dual mobility in primary and revision hip arthroplasty has continued to increase since 2012. However, after relatively stable usage rate over last three years, the use of dual mobility has declined slightly to 7.6% in 2022, from 8.8% in 2021. The registry considered this decline may be due to misclassifying dual mobility constructs as 28mm heads. This construct was most commonly used in the oldest ( $\geq$ 90) and youngest (<50 years) patient groups. The use of dual mobility has increased annually for hip revision due to dislocation/instability, from 12.9% in 2012 to 34.3% in 2022.<sup>4</sup>

### SAR

Dual mobility is mainly used for revisions. Dual mobility was first reported in 2002 (one revision case) and increased to 451 revisions per year between 2017 and 2019. This number has changed only slightly since then to date.<sup>6</sup>

20 | 52

Published by CeramTec GmbH CeramTec-Platz 1–9 | 73207 Plochingen, Germany Phone: +49 7153 611-513 ceranews@ceramtec.de | www.ceranews.com Stuttgart district court commercial register, no. 734826

VAT identification no. DE814031115

Responsible Editor: Dr. Henrich Mannel Concept and Editing: Florence Petkow, Dr. Alessandro Alan Porporati Design and Production: Fiona Lennartz

MD-IPM-00753 Version 1.0, August 2024

CeramTec is committed to selecting and bringing to interested parties relevant articles on bioceramics related topics. The presented authors' views and opinions are solely those of the authors of these publications. It is the focus and intent of CeraNews that CeramTec presents and comments on the authors' views and opinions in a specific context. Such comments and editorials therefore solely express CeramTec's views and opinions and not necessarily those of the quoted authors.

All statements are provided for educational purposes. For product, safety, and risk information, always refer to the labeling of the legal manufacturer. Ceramic experts

Conventional femoral BIOLOX® *delta* heads and inserts as well as BIOLOX®OPTION products are registered by CeramTec's customers. Products are not registered / available in all countries.

BIOLOX<sup>®</sup>delta, BIOLOX<sup>®</sup>OPTION, BIOLOX<sup>®</sup> and CeramTec are registered trademarks of the CeramTec Group, Germany. MatOrtho<sup>®</sup> and ReCerf<sup>®</sup> are trademarks of MatOrtho Limited. H<sup>®</sup> is a trademark of Embody Orthopaedic Limited.

©CeramTec GmbH 2024. All rights reserved.

### **OUTCOMES RESEARCH | REGISTRIES ANNUAL REPORTS 2023 IN REVIEW**

### **LROI**

In the Netherlands, dual mobility cup is used in 5.2% of all primary THRs in 2022, up from 1.4% in 2013. This type of acetabular cup is mainly used for hip revision surgeries in Netherlands, accounting for 48.1% of all hip revision surgeries in 2022, increasing from 32.2% in 2013 to 54% in 2021, then decreasing to 48.1% in 2022.7

Figure 11: Annual use of dual mobility bearings in primary THRs in the NJR, AJRR, EPRD, and LROI.





Evaluation of the data by CeramTec based on the NJR Annual Report 2023 Page 54 Table 3.H2, EPRD Annual Report 2019 to 2023 and AJRR Annual Report 2023 Page 39 Figure 2.18, LROI Annual Report 2023 Page 23 Figure Dual mobility. For the data from the NJR, the usage rates of dual mobility correspond to the sum of the usage rates of dual mobility bearings with different fixation methods. In order for the total number to be equal to the number of THRs, all data relating to hip resurfacing were excluded from the percentage calculation

# Published by CeramTec GmbH CeramTec-Platz 1–9 | 73207 Plochingen, Germany Phone: +49 7153 611-513 ceranews@ceramtec.de | www.ceranews.com Stuttgart district court commercial register, no. 734826 VAT identification no. DE814031115

Concept and Editing: Florence Petkow, Dr. Alessandro Alan Porporati Design and Production: Fiona Lennartz

CeramTec is committed to selecting and bringing to inter-ested parties relevant articles on bioceramics related topics. The presented authors' views and opinions are solely those of the authors of these publications. It is the focus and intent of CeraNews that CeramTec presents and comments on the authors' views and opinions in a specific context. Such comments and editorials therefore solely express CeramTec's views and opinions and not necessarily those of the quoted authors.

All statements are provided for educational purposes. For product, safety, and risk information, always refer to the labeling of the legal manufacturer.

Conventional femoral BIOLOX®*delta* heads and inserts as well as BIOLOX®OPTION products are registered by CeramTec's customers. Products are not registered / available in all countries

1 | 2024

### in 🖂 🌐

1 | 2024

### **Clinical Outcomes**

### **Reasons for Revision**

With regard to the most common reasons for revision, the terminologies used in the national registries varies slightly. There are also some differences between countries in the ordering of the main reasons. (Aseptic) loosening, infection, dislocation and (periprosthetic) fractures were at the top of the list, although with the order varied.

### 😹 NJR

The most common reasons for revision recorded by NJR of all the revision procedures were aseptic loosening, dislocation/subluxation, periprosthetic fracture, infection, and adverse soft tissue reaction to particulate debris.<sup>1</sup>

### 🛅 AOA NJRR

In 2022, infection (23.3%) is the most common reason for revision for all primary conventional THRs with primary diagnosis osteoarthritis (OA), followed by (periprosthetic) fracture (22.0%), prosthesis dislocation/instability (21.7%), and loosening (20.8%).

In 2022, the Australian registry conducted a comprehensive analysis of infections following primary hip, knee and shoulder replacements. The key messages on infections in hip replacement include:

- The number of revision procedures due to infection increased from 1.3% (333 revisions) of all hip surgeries in 2003 to 2.2% (1,173 revisions) in 2022. In contrast, all hip revisions for reasons other than infection decreased from 11.7% (3,111 revisions) in 2003 to 5.1% (2,690) in 2022.
- Across all age groups, revisions for infection are more common in males, while revisions for reasons other than infection are more common in females.
- For primary total conventional hip replacement with a primary diagnosis OA, the mean time to first revision due to infection is shorter than the mean time to first revision for reasons other than infection  $(1.8 \pm 3.1 \text{ years versus } 3.7 \pm 4.4 \text{ years post primary procedure}).$
- For primary total conventional hip replacement with primary diagnosis OA, of all first revision for infection, 45.2% (1,515 procedures) of all first revisions for infection were metal/XLPE, followed by ceramic/XLPE (28.9%, 968 procedures), then ceramic/ ceramic (12.6%, 422 procedures), and lastly ceramicised metal/XLPE (7.4%, 248

22 | 52

Published by CeramTec GmbH CeramTec-Platz 1–9 | 73207 Plochingen, Germany Phone: +49 7153 611-513 ceranews@ceramtec.de | www.ceranews.com Stuttgart district court commercial register, no. 734826

VAT identification no. DE814031115

Responsible Editor: Dr. Henrich Mannel Concept and Editing: Florence Petkow, Dr. Alessandro Alan Porporati Design and Production: Fiona Lennartz

MD-IPM-00753 Version 1.0, August 2024

CeramTec is committed to selecting and bringing to interested parties relevant articles on bioceramics related topics. The presented authors' views and opinions are solely those of the authors of these publications. It is the focus and intent of CeraNews that CeramTec presents and comments on the authors' views and opinions in a specific context. Such comments and editorials therefore solely express CeramTec's views and opinions and not necessarily those of the quoted authors.

All statements are provided for educational purposes. For product, safety, and risk information, always refer to the labeling of the legal manufacturer. Ceramic experts

Conventional femoral BIOLOX® *delta* heads and inserts as well as BIOLOX®OPTION products are registered by CeramTec's customers. Products are not registered / available in all countries.

BIOLOX<sup>®</sup>delta, BIOLOX<sup>®</sup>OPTION, BIOLOX<sup>®</sup> and CeramTec are registered trademarks of the CeramTec Group, Germany. MatOrtho<sup>®</sup> and ReCerf<sup>®</sup> are trademarks of MatOrtho Limited. H1<sup>®</sup> is a trademark of Embody Orthopaedic Limited.

©CeramTec GmbH 2024. All rights reserved.

procedures). Of all first revision surgeries performed for other reasons, 42.4% (4,684 procedures) were metal/XLPE, 21.6% (2,387 procedures) were ceramic/XLPE, then ceramic/ceramic (18.7%, 2,065), and finally ceramicised metal/XLPE (7.1%, 781 procedures).

- When primary hip replacements are revised due to infection, 51.1% are due to early • revisions, which the AOA NJRR defined as a revision within 3 months post primary procedure. Specifically, 24.1% occurs between 7 days and 4 weeks after primary procedure, 26.6% are revised in the period between 4 weeks and 3 months after primary procedure, 25.5% happens after 2 years.
- After first revision for infection, a risk of second revision for any reason is as high as 45.3% at 10 years.<sup>2</sup>

### EPRD

EPRD still provides data on reasons for revision based on procedures performed in the operation year. In 2022, loosening (22.7%), infection (16.4%), periprosthetic fracture (15.9%), dislocation (13.6%), and implant wear (5.8%) were the most common reasons for revision. Revision rates for loosening decreased each year, from 43.7% in 2014 to 22.7% in 2022. In contrast, revision rates due to infection increased from 10.1% in 2014 to 16.4% in 2022.3

### **AJRR**

Infection and inflammatory reaction (22.5%) remain the most common reason for all revisions recorded in the American registry, followed by mechanical complications (20.8%), instability related codes (20.7%), aseptic loosening (19.7%) and pain (14.3%).<sup>4</sup>

### **NZJR**

Since 1999, the six main reasons for revision after THR procedures in New Zealand are: loosening (of the acetabular and femoral component, respectively), dislocation/instability, unexplained pain, deep infection, and fracture femur. Deep infection and dislocation are more often happened within the first year after operation. On the other hand, loosening is a more common indication for revision beyond 10 years after operation.<sup>5</sup>

### SAR

The most common reasons for revision surgery in the period 2020 to 2022 were: loosening, infection, peri-prosthetic fracture, and dislocation/instability. The percentage of revisions due to loosening has decreased, while the percentage of infection has increased. A high number of revisions due to pseudotumors (ALVAL, Aseptic Lymphocytedominated Vasculitis-Associated Lesions or ALTR, Adverse Local Tissue Reaction belong to this category acc. to the registry report) was noted especially at the beginning of the period from 2014 to 2016, then decreased significantly thereafter. Ten cases were 23 | 52 reported in 2022.6

Published by Ceram Tec GmbH Ceram Tec-Platz 1–9 | 73207 Plochingen, Germany Phone: +49 7153 611-513 ceranews@ceramtec.de | www.ceranews.com Stuttgart district court commercial register, no. 734826

Concept and Editing: Florence Petkow, Dr. Alessandro Alan Porporati Design and Production: Fiona Lennartz

CeramTec is committed to selecting and bringing to inter-ested parties relevant articles on bioceramics related topics. The presented authors' views and opinions are solely those of the authors of these publications. It is the focus and intent of CeraNews that CeramTec presents and comments on the authors' views and opinions in a specific context. Such comments and editorials therefore solely express CeramTec's views and opinions and not necessarily those of the quoted authors

All statements are provided for educational purposes. For product, safety, and risk information, always refer to the labeling of the legal manufacturer.



Conventional femoral BIOLOX® *delta* heads and inserts as well as BIOLOX® OPTION products are registered by CeramTec's customers. Products are not registered / available in all

(in) 🖂 🌐

### **LROI**

The most common reasons for revision recorded by LROI of all revision procedures between 2014 and 2022 were loosening of acetabulum component (21.2%), infection (20.9%), dislocation (18.6%), loosening of femur component (18.2%), and inlay wear (16.5%). The annual revision for infection increased from 12.3% in 2014 to 23.9% in 2022.7



### The Most Common Reasons for Revision



24 | 52

Conventional femoral BIOLOX®*delta* heads and inserts as well as BIOLOX®OPTION products are registered by CeramTec's customers. Products are not registered / available in all countries

reasons for revision in England, Wales, Northern Ireland, the Isle of Man and Guernsey, Australia, the United States and the Netherlands.

Figure 12: The most common

# Published by CeramTec GmbH CeramTec-Platz 1–9 | 73207 Plochingen, Germany Phone: +49 7153 611-513 ceranews@ceramtec.de | www.ceranews.com Stuttgart district court commercial register, no. 734826 VAT identification no. DE814031115

Concept and Editing: Florence Petkow, Dr. Alessandro Alan Porporati Design and Production: Fiona Lennartz

CeramTec is committed to selecting and bringing to inter-ested parties relevant articles on bioceramics related topics. The presented authors' views and opinions are solely those of the authors of these publications. It is the focus and intent of CeraNews that CeramTec presents and comments on the authors' views and opinions in a specific context. Such comments and editorials therefore solely express CeramTec's views and opinions and not necessarily those of the quoted authors.

All statements are provided for educational purposes. For product, safety, and risk information, always refer to the labeling of the legal manufacturer.

1 | 2024

### OUTCOMES RESEARCH | REGISTRIES ANNUAL REPORTS 2023 IN REVIEW

in 🖂





Evaluation of the data by CeramTec based on the NJR Annual Report 2023 Page 106, the reasons for revision recorded in the NJR are not mutually exclusive. AOA NJRR Annual Report 2023 Page 118 Table HT15, and AJRR Annual Report 2023 Page 56 Figure 2.32, LROI Annual Report 2023 Page 34 Figure Reasons for revision.

25 | 52

Published by CeramTec GmbH CeramTec-Platz 1–9 | 73207 Plochingen, Germany Phone: +49 7153 611-513 ceranews@ceramtec.de | www.ceranews.com Stuttgart district court commercial register, no. 734826 VAT identification no. DE814031115

Responsible Editor: Dr. Henrich Mannel Concept and Editing: Florence Petkow, Dr. Alessandro Alan Porporati Design and Production: Fiona Lennartz

CeramTec is committed to selecting and bringing to inter-ested parties relevant articles on bioceramics related topics. The presented authors' views and opinions are solely those of the authors of these publications. It is the focus and intent of CeraNews that CeramTec presents and comments on the authors' views and opinions in a specific context. Such comments and editorials therefore solely express CeramTec's views and opinions and not necessarily those of the quoted authors.

All statements are provided for educational purposes. For product, safety, and risk information, always refer to the labeling of the legal manufacturer.

Conventional femoral BIOLOX®*delta* heads and inserts as well as BIOLOX®OPTION products are registered by CeramTec's customers. Products are not registered / available in all

1|2024

### **Trends in Reasons for Revision**

In Annual Report 2023, EPRD shows the following developments in the percentage shares of various treatment characteristics in primary THRs from 2012/13 to 2022, such as: fixation, insert materials, head sizes, head neck length as well as reasons for revision. As shown in the EPRD, revision rate due to loosening is decreasing each year. The revisions due to infection increased from 10.1% in 2014 to 16.4% in 2022. Similarly, the revision rates due to infections documented by the AJRR varies from 10.9% to 22.6% between 2012 and 2020, and then stabilized at about 23% in 2021 and 2022 (AJRR Annual Report 2023 Page 58 Figure 2.35). In the Netherlands, the annual revision for infection increased from 12.3% in 2014 to 25.3% in 2021 and then declined slightly to 23.9% in 2022. The NZJR has also provided insight into the year-on-year trends of their six main reasons for revision. The revision rate due to deep infection increased from 8.6% in 2012 to 19.3% in 2022. The revision rate due to fracture femur has steadily increased from 9.3% in 2013 to 21.5% in 2022. On the other hand, the revision rate due to unexplained pain declined from a peak of 20.6% in 2011 to 9.4% in 2020, then to the lowest point recorded in the registry in almost a decade, namely 3.6% in 2022.



### Figure 13: Reasons for revision by year in Germany.

Evaluation of the data by CeramTec based on EPRD Annual Report 2023 Page 37 Figure 7.

26 | 52

Published by CeramTec GmbH CeramTec-Platz 1–9 | 73207 Plochingen, Germany Phone: +49 7153 611-513 ceranews@ceramtec.de | www.ceranews.com Stuttgart district court commercial register, no. 734826

Stuttgart district court commercial register, no. 734826 VAT identification no. DE814031115

Responsible Editor: Dr. Henrich Mannel Concept and Editing: Florence Petkow, Dr. Alessandro Alan Porporati Design and Production: Fiona Lennartz

MD-IPM-00753 Version 1.0, August 2024

CeramTec is committed to selecting and bringing to interested parties relevant articles on bioceramics related topics. The presented authors' views and opinions are solely those of the authors of these publications. It is the focus and intent of CeraNews that CeramTec presents and comments on the authors' views and opinions in a specific context. Such comments and editorials therefore solely express CeramTec's views and opinions and not necessarily those of the quoted authors.

All statements are provided for educational purposes. For product, safety, and risk information, always refer to the labeling of the legal manufacturer.

Conventional femoral BIOLOX®delta heads and inserts as well as BIOLOX®OPTION products are registered by CeramTec's customers. Products are not registered / available in all countries.

BIOLOX<sup>®</sup>delta, BIOLOX<sup>®</sup>OPTION, BIOLOX<sup>®</sup> and CeramTec are registered trademarks of the CeramTec Group, Germany. MatOrtho<sup>®</sup> and ReCerf<sup>®</sup> are trademarks of MatOrtho Limited. H<sup>®</sup> is a trademark of Embody Orthopaedic Limited.

©CeramTec GmbH 2024. All rights reserved

### 2024

### **OUTCOMES RESEARCH | REGISTRIES ANNUAL REPORTS 2023 IN REVIEW**

in 🖂

Figure 14: Reasons for revision by year in the Netherlands.

INSIGHTS



Evaluation of the data by CeramTec based LROI Annual Report 2023 Page 34 Figure Reasons for revision.

Figure 15: Reasons for revision by year in New Zealand.



Evaluation of the data by CeramTec based NZJR Annual Report 2023 Page 21 Table 1.17.

#### 27 | 52

Published by CeramTec GmbH CeramTec-Platz 1–9 | 73207 Plochingen, Germany Phone: +49 7153 611-513 ceranews@ceramtec.de | www.ceranews.com Stuttgart district court commercial register, no. 734826 VAT identification no. DE814031115

Responsible Editor: Dr. Henrich Mannel Concept and Editing: Florence Petkow, Dr. Alessandro Alan Porporati Design and Production: Fiona Lennartz

CeramTec is committed to selecting and bringing to inter-ested parties relevant articles on bioceramics related topics. The presented authors' views and opinions are solely those of the authors of these publications. It is the focus and intent of CeraNews that CeramTec presents and comments on the authors' views and opinions in a specific context. Such comments and editorials therefore solely express CeramTec's views and opinions and not necessarily those of the quoted authors.

All statements are provided for educational purposes. For product, safety, and risk information, always refer to the labeling of the legal manufacturer.

Conventional femoral BIOLOX®*delta* heads and inserts as well as BIOLOX®OPTION products are registered by Ceram Tec's customers. Products are not registered / available in all

### 

1|2024

### **Revision Rates**

### 😹 NJR

By the end of 2022, the NJR has recorded a total of 1,448,541 primary hip replacements over the lifetime of the registry, of which 43,682 (3%) were linked first revisions. It can be observed that the number of revisions increased each year from 2003 to 2008 and decreased each year from 2008 to 2022. The NJR is reporting a maximum of 19.75 years of follow-up.

Across all fixation methods, CoP bearings have consistently maintained a low or similar rate of revision to those of other bearings up to fifteen years. The excellent results encourage wider use of CoP bearings.

As the number of cases recorded by NJR increases, the confidence intervals narrow and statistical significance is reached for both genders, all age groups, and up to 18 years after implantation. This year, the results obtained in younger patients by CoC and CoP are statistically better than those obtained by MoP; the NJR 2023 Annual Report states that these results are "striking". For male patients aged 55 to 64 years, CoP and CoC with hybrid fixation, CoP and CoC with uncemented fixation, as well as cemented CoP bearings have relatively low revision rates, about below 5% at 15 years postoperatively. In contract, the revision rate of cemented MoP bearings and uncemented MoP were 8.26% and 7.06%, respectively. For female patients aged 55 to 64 years old, the revision rates of hybrid CoC was 3.05% (95% CI 2.58%-3.59%) at 15 years.

As shown in Figure 16, in the cemented fixation group, CoP bearings with 36mm heads had higher revision rates than those with 28- and 32mm heads. Correspondingly, in the uncemented and hybrid fixation groups, CoP bearings with 32- and 36mm heads had lower revision rates than 28mm heads.

In the uncemented fixation group, there is a clear correlation between the revision rates of CoC bearings and head size: the larger the head, the lower the revision rate of the construct (except for 44mm heads after six years). In the hybrid fixation group, the revision rate of CoC bearings with 36mm heads was higher than that of 32- and 28mm heads (p=0.001).

This annual report indicates that the early failure rate of MoPoM in uncemented and hybrid group were higher than most bearings. At this point, CoPoM performs better but with a small number.

#### 28 | 52

Published by CeramTec GmbH CeramTec-Platz 1–9 | 73207 Plochingen, Germany Phone: +49 7153 611-513 ceranews@ceramtec.de | www.ceranews.com Stuttgart district court commercial register, no. 734826

Stuttgart district court commercial register, no. 734826 VAT identification no. DE814031115

Responsible Editor: Dr. Henrich Mannel Concept and Editing: Florence Petkow, Dr. Alessandro Alan Porporati Design and Production: Fiona Lennartz

MD-IPM-00753 Version 1.0, August 2024

CeramTec is committed to selecting and bringing to interested parties relevant articles on bioceramics related topics. The presented authors' views and opinions are solely those of the authors of these publications. It is the focus and intent of CeraNews that CeramTec presents and comments on the authors' views and opinions in a specific context. Such comments and editorials therefore solely express CeramTec's views and opinions and not necessarily those of the quoted authors

All statements are provided for educational purposes. For product, safety, and risk information, always refer to the labeling of the legal manufacturer. THE CERAMIC EXPERTS

Conventional femoral BIOLOX®*delta* heads and inserts as wel as BIOLOX®OPTION products are registered by CeramTec's customers. Products are not registered / available in all countries.

BIOLOX® delta, BIOLOX® OPTION, BIOLOX® and CeramTec are registered trademarks of the CeramTec Group, Germany. MatOrtho® and ReCerf® are trademarks of MatOrtho Limited. H® is a trademark of Embody Orthopaedic Limited.

©CeramTec GmbH 2024. All rights reserved

### in 🖂

1 | 2024

Figure 16: Cumulative revision rates in primary hip replacement with Mop, CoP, and CoC bearings in combination with different fixation methods in England, Wales, Northern Ireland, the Isle of Man and Guernsey.

### ×

### **Revision Rates in Primary THRs by Fixation and Bearing Type**







Evaluation of the data by CeramTec based on the NJR Annual Report 2023 Page 69 Table 3.H5.

29 | 52

Published by CeramTec GmbH CeramTec-Platz 1–9 | 73207 Plochingen, Germany Phone: +49 7153 611-513 ceranews@ceramtec.de | www.ceranews.com Stuttgart district court commercial register, no. 734826 VAT identification no. DE814031115

Responsible Editor: Dr. Henrich Mannel Concept and Editing: Florence Petkow, Dr. Alessandro Alan Porporati Design and Production: Fiona Lennartz

CeramTec is committed to selecting and bringing to inter-ested parties relevant articles on bioceramics related topics. The presented authors' views and opinions are solely those of the authors of these publications. It is the focus and intent of CeraNews that CeramTec presents and comments on the authors' views and opinions in a specific context. Such comments and editorials therefore solely express CeramTec's views and opinions and not necessarily those of the quoted authors.

All statements are provided for educational purposes. For product, safety, and risk information, always refer to the labeling of the legal manufacturer.

Conventional femoral BIOLOX® *delta* heads and inserts as well as BIOLOX®OPTION products are registered by CeramTec's customers. Products are not registered / available in all

CoC resurfacing is recorded by the NJR for the first time in 2022, although this construct is still undertaken in small numbers (N=249). The early revision rate at 1 year for CoC resurfacing is similar to that for MoM resurfacing (1.27% (0.41%-3.87%) vs. 1.18% (1.08%-1.29%)), and lower at 3 years (1.91% (0.71%-5.11%) vs. 2.90% (2.74%-3.06%)) and 5 years (1.91% (0.71%-5.11%) vs. 5.06% (4.85%-5.28%)). The NJR reminds readers to be cautious in interpreting this difference due to the small number of CoC resurfacing. (Figure 17)

Figure 17: Cumulative revision rates in primary hip replacement with Resurfacing MoM and Resurfacing CoC in England, Wales, Northern Ireland, the Isle of Man and Guernsey.





Evaluation of the data by CeramTec based on the NJR Annual Report 2023 Page 69 Table 3.H5.

30 | 52

Published by CeramTec GmbH CeramTec-Platz 1–9 | 73207 Plochingen, Germany Phone: +49 7153 611-513 ceranews@ceramtec.de | www.ceranews.com Stuttgart district court commercial register, no. 734826 VAT identification no. DE814031115

Concept and Editing: Florence Petkow, Dr. Alessandro Alan Porporati Design and Production: Fiona Lennartz

CeramTec is committed to selecting and bringing to inter-ested parties relevant articles on bioceramics related topics. The presented authors' views and opinions are solely those of the authors of these publications. It is the focus and intent of CeraNews that CeramTec presents and comments on the authors' views and opinions in a specific context. Such comments and editorials therefore solely express CeramTec's views and opinions and not necessarily those of the quoted authors.

All statements are provided for educational purposes. For product, safety, and risk information, always refer to the labeling of the legal manufacturer.



1 | 2024

(in) 🖂 🌐

Conventional femoral BIOLOX® *delta* heads and inserts as well as BIOLOX® OPTION products are registered by CeramTec's customers. Products are not registered / available in all

1 | 2024

(in) 🖂 🌐

### 🛅 AOA NJRR

According to AOA NJRR Annual Report 2023, the 20-year cumulative revision rate of all primary total conventional hip replacement procedures with primary diagnosis OA is 8.1%.

In Australia, CoXLPE shows a lower rate of revision than MoXLPE after 2 years significantly (0.77 (0.72, 0.82), p<0.001). According to the Australian registry analysis, the revision rate of CoC is not statistically different from MoXLPE at entire period (HR=0.99 (0.96,1.03), p=0.770) (Figure 18).

The lowest revision rate of revision is given by ceramicised metal heads coupled with XLPE liners, which is statistically different from MoXLPE (after 1 year: HR=0.62 (0.56,0.69), p<0.001). However, the registry urges caution in the interpretation of this result as in the previous reports since "*This bearing is a single company product, used with a small number of femoral stem and acetabular component combinations. This may have a confounding effect on the outcome, making it unclear if the lower rate of revision is an effect of the bearing surface or reflects the limited combinations of femoral and acetabular prostheses.*"

As far as the head size is concerned, the 32mm XLPE was associated with a lower rate of revision in comparison with larger heads and smaller heads (XLPE >32mm vs XLPE 32mm after one months: HR=1.13 (1.07, 1.19), p<0.001; XLPE <32mm vs XLPE 32mm after 1.5 year: HR=1.20 (1.11, 1.28), p<0.001) (Figure 19).

For CoC bearings with mixed ceramic (Figure 20), there is no significant difference in the rate of revision between 36-38mm and 32mm head sizes (HR=1.01 (0.88, 1.16), p=0.898). Further, also the revision rates of 36-38mm and ≥40mm head sizes are also not statistically different over the entire period (HR=0.95 (0.77, 1.17), p=0.634), also for ≥40mm versus 32mm head sizes (HR=1.06 (0.83, 1.36), p=0.632). However, the ≤28mm head sizes are associated with a higher revision rate within the first three months (HR=2.38 (1.36, 4.17), p=0.002) compared to 32mm head sizes.

Compared to XLPE + antioxidant, XLPE has a higher revision rate after 3 years (HR=1.29 (1.09, 1.53), p=0.002).

Dual mobility constructs have a lower revision for dislocation/instability compared to other acetabular prosthesis (HR=0.54 (0.41, 0.71), p<0.001). Female patients undergoing a hip procedure with a dual mobility construct have a lower rate of all cause revision compared to male (HR=0.75 (0.61, 0.92), p=0.005).

The revision rate (at 1 year) of the MatOrtho ReCerf® CoC resurfacing has been reported for the first time by the AOA NJRR in 2020. In 2022, 42 new procedures have been reported. The Australian Registry showed that the revision rate at 1 year of MatOrtho ReCerf® CoC resurfacing (0.3 (0.0, 2.1)) and at 3 years (0.3 (0.0, 2.1)), with only 1 revision of all 346 procedures, was lower than other MoM resurfacing.<sup>2</sup> 31 | 52

Published by CeramTec GmbH CeramTec-Platz 1–9 | 73207 Plochingen, Germany Phone: +49 7153 611-513 ceranews@ceramtec.de | www.ceranews.com Stuttgart district court commercial register, no. 734826

VAT identification no. DE814031115

Responsible Editor: Dr. Henrich Mannel Concept and Editing: Florence Petkow, Dr. Alessandro Alan Porporati Design and Production: Fiona Lennartz

MD-IPM-00753 Version 1.0, August 2024

CeramTec is committed to selecting and bringing to interested parties relevant articles on bioceramics related topics. The presented authors' views and opinions are solely those of the authors of these publications. It is the focus and intent of CeraNews that CeramTec presents and comments on the authors' views and opinions in a specific context. Such comments and editorials therefore solely express CeramTec's views and opinions and not necessarily those of the quoted authors.

All statements are provided for educational purposes. For product, safety, and risk information, always refer to the labeling of the legal manufacturer.

Conventional femoral BIOLOX® *delta* heads and inserts as well as BIOLOX®OPTION products are registered by CeramTec's customers. Products are not registered / available in all countries.

BIOLOX<sup>®</sup> delta, BIOLOX<sup>®</sup> OPTION, BIOLOX<sup>®</sup> and CeramTec are registered trademarks of the CeramTec Group, Germany. MatOrtho<sup>®</sup> and ReCerf<sup>®</sup> are trademarks of MatOrtho Limited. H1<sup>®</sup> is a trademark of Embody Orthopaedic Limited.

©CeramTec GmbH 2024. All rights reserved

\*

₩..

in 🖂

Figure 18: Cumulative revision rates in primary THRs with CoXLPE, MoXLPE and CoC bearings (Primary Diagnosis OA) in Australia.

**INSIGHTS** 

### **Cumulative Revision Rates in Primary THRs** with CoXLPE, MoXLPE and CoC bearings



Evaluation of the data by CeramTec based on the AOA NJRR Annual Report 2023 Page 146 Table HT34.

Figure 19: Cumulative revision rates of XLPE acetabulum in primary THRs by head size (Primary Diagnosis OA, restricted to modern prostheses).

Figure 20: Cumulative revision

of mixed ceramic/mixed ceramic bearings (Primary

size in Australia.

Diagnosis OA, restricted to

modern prostheses) by head



### **Cumulative Revisions of XLPE Acetabulum** in Primary THRs by Head Size and by Year

Evaluation of the data by CeramTec based on the AOA NJRR Annual Report 2023 Page 149 Table HT35.

### \*

#### Cumulative Revision of Mixed Ceramic/Mixed Ceramic in Primary THRs by Head Size



Evaluation of the data by CeramTec based on AOA NJRR Annual Report 2023 Page 159 Table HT40.

32 | 52

Published by CeramTec GmbH CeramTec-Platz 1–9 | 73207 Plochingen, Germany Phone: +49 7153 611-513 ceranews@ceramtec.de | www.ceranews.com Stuttgart district court commercial register, no. 734826 VAT identification no. DE814031115

Concept and Editing: Florence Petkow, Dr. Alessandro Alan Porporati Design and Production: Fiona Lennartz

CeramTec is committed to selecting and bringing to inter-ested parties relevant articles on bioceramics related topics. The presented authors' views and opinions are solely those of the authors of these publications. It is the focus and intent of CeraNews that CeramTec presents and comments on the authors' views and opinions in a specific context. Such comments and editorials therefore solely express CeramTec's views and opinions and not necessarily those of the quoted authors.

All statements are provided for educational purposes. For product, safety, and risk information, always refer to the labeling of the legal manufacturer.

Conventional femoral BIOLOX® *delta* heads and inserts as well as BIOLOX® OPTION products are registered by CeramTec's customers. Products are not registered / available in all

### in 🖂 🌐

1|2024

### EPRD

Among all bearings in elective primary THRs with uncemented stem fixation (uncemented fixation and reverse hybrid fixation), CoC had a significantly lower revision rate over the entire period than the other bearings, with the exception of CohXLPE+Antioxidants (Figure 21). Among all bearing couples in elective primary THRs, the revision rate of bearings with metal heads was significantly higher than that of bearings with ceramic heads in both cemented and uncemented stem fixation groups.

When comparing revision rates among different fixation groups, the results did not show big different between the cemented and uncemented fixation groups, which is not in line with the results observed from other registry reports (Figure 22).<sup>3</sup>

In both cemented stem fixation group and uncemented stem fixation group, 36mm head size show a lower cumulative revision rate along seven years (Figure 23).

Cumulative Revision Rates of CohXLPE, CohXLPE+Antiox, CoC and

Figure 21: Cumulative revision rates of CohXLPE, CohXLPE+Antiox, CoC and MohXLPE in elective hip replacements by stem fixation in Germany.







Evaluation of the data by CeramTec based on EPRD Annual Report 2023 Page 82 Table 46.

33 | 52

Published by CeramTec GmbH CeramTec-Platz 1–9 | 73207 Plochingen, Germany Phone: +49 7153 611-513 ceranews@ceramtec.de | www.ceranews.com Stuttgart district court commercial register, no. 73482

VAT identification no. DE814031115

Responsible Editor: Dr. Henrich Mannel Concept and Editing: Florence Petkow, Dr. Alessandro Alan Porporati Design and Production: Fiona Lennartz

MD-IPM-00753 Version 1.0, August 2024

Ceram tec is committed to selecting and bringing to interested parties relevant articles on bioceramics related topics. The presented authors' views and opinions are solely those of the authors of these publications. It is the focus and intent of CeraNews that Ceram Tec presents and comments on the authors' views and opinions in a specific context. Such comments and editorials therefore solely express CeramTec's views and opinions and not necessarily those of the quoted authors.

All statements are provided for educational purposes. For product, safety, and risk information, always refer to the labeling of the legal manufacturer. Cerantec Experts

Conventional femoral BIOLOX®delta heads and inserts as well as BIOLOX®OPTION products are registered by CeramTec's customers. Products are not registered / available in all countries.

BIOLOX<sup>®</sup>delta, BIOLOX<sup>®</sup>OPTION, BIOLOX<sup>®</sup> and CeramTec are registered trademarks of the CeramTec Group, Germany. MatOrtho<sup>®</sup> and ReCerf<sup>®</sup> are trademarks of MatOrtho Limited. H1<sup>®</sup> is a trademark of Embody Orthopaedic Limited.

©CeramTec GmbH 2024. All rights reserved

(in 🖂 🌐

Figure 22: Cumulative revision rates of different fixations in elective hip replacements in Germany.

**INSIGHTS** 

#### Cumulative Revisions of Fixations in Elective Hip Replacements



Evaluation of the data by CeramTec based on EPRD Annual Report 2023 Page 82 Table 46.

Figure 23: Cumulative revision rates of head size in elective hip replacements with different fixations in Germany.

### Cumulative Revision of Elective Hip Replacements with Uncemented Stems by Head Size



Evaluation of the data by CeramTec based on EPRD Annual Report 2023 Page 82 Table 46.

### AJRR

For patients above 65 years who underwent elective primary THRs, the cumulative revision rate was higher when using smaller heads ( $\leq$ 28mm) and larger heads ( $\geq$ 40mm) than those procedures with 36mm heads. No statistical difference was found between 36mm heads and 32mm heads.<sup>4</sup>

#### 📉 NZJR

The New Zealand registry uses two very specific statistical terms for revision rates that are not found in the other registries:

**Observed component years:** the number of registered primary procedures multiplied by the number of years each component has been in place.

**Rate/100 component years:** equivalent to the yearly revision rate expressed as a percentage figure derived by dividing the number of prostheses revised by the observed component years multiplied by 100.

34 | 52

Published by CeramTec GmbH CeramTec-Platz 1–9 | 73207 Plochingen, Germany Phone: +49 7153 611-513 ceranews@ceramtec.de | www.ceranews.com Stuttgart district court commercial register, no. 734826 VAT identification no. DE814031115

Responsible Editor: Dr. Henrich Mannel Concept and Editing: Florence Petkow, Dr. Alessandro Alan Porporati Design and Production: Fiona Lennartz

MD-IPM-00753 Version 1.0, August 2024

CeramTec is committed to selecting and bringing to interested parties relevant articles on bioceramics related topics. The presented authors' views and opinions are solely those of the authors of these publications. It is the focus and intent of CeraNews that CeramTec presents and comments on the authors' views and opinions in a specific context. Such comments and editorials therefore solely express CeramTec's views and opinions and not necessarily those of the quoted authors.

All statements are provided for educational purposes. For product, safety, and risk information, always refer to the labeling of the legal manufacturer. Ceramic experts

Conventional femoral BIOLOX® *delta* heads and inserts as well as BIOLOX®OPTION products are registered by CeramTec's customers. Products are not registered / available in all countries.

BIOLOX<sup>®</sup>delta, BIOLOX<sup>®</sup>OPTION, BIOLOX<sup>®</sup> and CeramTec are registered trademarks of the CeramTec Group, Germany. MatOrtho<sup>®</sup> and ReCerf<sup>®</sup> are trademarks of MatOrtho Limited. H<sup>®</sup> is a trademark of Embody Orthopaedic Limited.

©CeramTec GmbH 2024. All rights reserved

(in) 🖂 🌐

# INSIGHTS

### **OUTCOMES RESEARCH | REGISTRIES ANNUAL REPORTS 2023 IN REVIEW**

The NZJR shows that CoC bearings have the lowest revision rate with all head sizes in all age groups, despite the use of CoC bearings is declined.

When comparing revision rate of different head size groups, in general, 32mm head size had a lower revision rate compared to the other head sizes.<sup>5</sup>

#### Table 2: Revision data by bearing type in New Zealand.

Evaluation of the data by CeramTec based on the NZJR Annual Report 2023 Page 25 Table 1.29.

Surface	Numbers of operations	Observed component years	Number Revised	Rate/100 component years (95%)
CoC	16,050	148,342.7	710	0.48 (0.44-0.52)
CoP	50,449	334,764.7	1,963	0.59 (0.56-0.61)
MoP	92,658	811,147.1	5,279	0.65 (0.63-0.67)

### Table 3: Revision data by head size in New Zealand.

Evaluation of the data by CeramTec based on the NZJR Annual Report 2023 Page 25 Table 1.30.

Head Size (mm)	Numbers of operations	Observed component years	Number Revised	Rate/100 component years (95%)
≤28mm	66,908	756,826.3	5,334	0.7 (0.69-0.72)
32mm	67,939	419,454.0	2,138	0.51 (0.49-0.53)
36mm	31,798	187,530.7	1,147	0.61 (0.58-0.65)
>36mm	4,182	35,822.4	693	1.93 (1.79-2.08)

### LROI

LROI analyzed the cumulative major revision rate of THRs for OA by different bearings in 2007-2022. CoC had a significantly lower cumulative major revision rate compared to CoP and MoP at 10 years. The difference between CoC and CMoP was not significant (Figure 24).

35 | 52

Published by CeramTec GmbH CeramTec-Platz 1–9 | 73207 Plochingen, Germany Phone: +49 7153 611-513 ceranews@ceramtec.de | www.ceranews.com Stuttgart district court commercial register, no. 734826 VAT identification no. DE814031115

Concept and Editing: Florence Petkow, Dr. Alessandro Alan Porporati Design and Production: Fiona Lennartz

CeramTec is committed to selecting and bringing to inter-ested parties relevant articles on bioceramics related topics. The presented authors' views and opinions are solely those of the authors of these publications. It is the focus and intent of CeraNews that CeramTec presents and comments on the authors' views and opinions in a specific context. Such comments and editorials therefore solely express CeramTec's views and opinions and not necessarily those of the quoted authors.

All statements are provided for educational purposes. For product, safety, and risk information, always refer to the labeling of the legal manufacturer.

Conventional femoral BIOLOX® *delta* heads and inserts as well as BIOLOX®OPTION products are registered by CeramTec's customers. Products are not registered / available in all

### 1 | 2024

### **OUTCOMES RESEARCH | REGISTRIES ANNUAL REPORTS 2023 IN REVIEW**

in 🖂

Figure 24: Cumulative major revisions of bearings in primary THRs in the Netherlands.

Figure 25: Cumulative revisions for dislocation by

head sizes in the Netherlands.

INSIGHTS



Evaluation of the data by CeramTec based LROI Annual Report 2023 Page 60 Table Cumulative major revision percentages.

As far as the head size is concerned, the 36mm femoral head (0.9% (0.7%-1.1%)) associated with a lower rate of revision for dislocation at a 14-year in comparison with the 32mm (1.1% (1.0%-1.2%)) head and 22-28mm head (1.8% (1.7%-2.0%)) at 14-year (Figure 25).7



Evaluation of the data by CeramTec based LROI Annual Report 2023 Page 59 Table Cumulative revision percentages for dislocation.

36 | 52

Published by CeramTec GmbH CeramTec-Platz 1–9 | 73207 Plochingen, Germany Phone: +49 7153 611-513 ceranews@ceramtec.de | www.ceranews.com Stuttgart district court commercial register, no. 734826 VAT identification no. DE814031115

Concept and Editing: Florence Petkow, Dr. Alessandro Alan Porporati Design and Production: Fiona Lennartz

CeramTec is committed to selecting and bringing to inter-ested parties relevant articles on bioceramics related topics. The presented authors' views and opinions are solely those of the authors of these publications. It is the focus and intent of CeraNews that CeramTec presents and comments on the authors' views and opinions in a specific context. Such comments and editorials therefore solely express CeramTec's views and opinions and not necessarily those of the quoted authors.

All statements are provided for educational purposes. For product, safety, and risk information, always refer to the labeling of the legal manufacturer.

Conventional femoral BIOLOX® *delta* heads and inserts as well as BIOLOX® OPTION products are registered by CeramTec's customers. Products are not registered / available in all

### in 🖂 🌐

### Patient-Reported Outcome Measures (PROMs)

PROMs calculate the health gains after surgical treatment from a patient perspective. This can contribute to the analysis of revision rates, identifying patients with persistent pain or disability as well as measuring patient satisfaction after surgery. Therefore, many registries and hospitals have started to record PROMs data. There is a growing demand for feasible methods and instruments to collect comprehensive PROMs and to enable data comparison between the registries.

### 😹 NJR

In 2022, due to significant changes on processing of Hospital Episode Statistics data and its linked PROMs data, the NJR was not able to secure access to the NHS datasets, resulting a pause in reporting PROMs this year.<sup>1</sup>

### 🛅 AOA NJRR

In 2022, the Australian Registry starts to report PROMs in a supplementary report. The Australian Registry uses the EQ-VAS and EQ-5D-5L to measure quality of life and uses Oxford Hip Score (OHS) to assess pain and function. In general, a large improvement of quality of life, joint-specified pain and function has been achieved for all classes of joint replacement. Of all recorded 22,130 primary total conventional hip replacements with primary diagnosis OA, mean pre-operative EQ-VAS is  $66.20 \pm 20.01$ , and mean post-operative of 14,502 procedures is  $80.86 \pm 15.83$ . The mean pre-operative OHS of 22,139 primary total conventional is  $20.92 \pm 8.98$  and this improves to  $41.45 \pm 7.23$  for 14,521 total conventional post-operatively. 90.9% of patients were either very satisfied or satisfied, while 96.7% of patients believed that their hip much better or a little better post-operatively.<sup>2</sup>

### AJRR 📃

496 sites out of 1,364 (36%) have submitted PROMs until December 31.2022, marking a 24% increase compared to the previous Annual Report. Results of the HOOS, JR. score show that 92% of the patients achieved a meaningful improvement after elective primary THRs.<sup>4</sup>

### 🐸 NZJR

The NZJR was one of the first joint registries to collect PROMs data. The validated Oxford Hip outcome questionnaires were sent out on a random selection basis to achieve an annual response rate of 20%. Oxford-12 questionnaire which includes 12 questions with score points ranging from 0 to 4. The maximum score of 48 indicates normal function, 0 stands for most severe disability.

According to the statistic recorded in the NZJR Annual Report 2023, the average scores at six months are 40.3, 84% had an excellent or good score (>34), 89% of these patients  $_{37|52}$ 

Published by CeramTec GmbH CeramTec-Platz 1–9 | 73207 Plochingen, Germany Phone: +49 7153 611-513 ceranews@ceramtec.de | www.ceranews.com Stuttgart district court commercial register, no. 73482

VAT identification no. DE814031115

Responsible Editor: Dr. Henrich Mannel Concept and Editing: Florence Petkow, Dr. Alessandro Alan Porporati Design and Production: Fiona Lennartz

MD-IPM-00753 Version 1.0, August 2024

CeramTec is committed to selecting and bringing to interested parties relevant articles on bioceramics related topics. The presented authors' views and opinions are solely those of the authors of these publications. It is the focus and intent of CeraNews that CeramTec presents and comments on the authors' views and opinions in a specific context. Such comments and editorials therefore solely express CeramTec's views and opinions and not necessarily those of the quoted authors.

All statements are provided for educational purposes. For product, safety, and risk information, always refer to the labeling of the legal manufacturer.

### CEPANIC EXPERTS

Conventional femoral BIOLOX® *delta* heads and inserts as well as BIOLOX®OPTION products are registered by CeramTec's customers. Products are not registered / available in all countries.

BIOLOX<sup>®</sup>delta, BIOLOX<sup>®</sup>OPTION, BIOLOX<sup>®</sup> and CeramTec are registered trademarks of the CeramTec Group, Germany. MatOrtho<sup>®</sup> and ReCerf<sup>®</sup> are trademarks of MatOrtho Limited. H<sup>®</sup> is a trademark of Embody Orthopaedic Limited.

©CeramTec GmbH 2024. All rights reserved.

achieved an excellent or good score with an average of 42.4 after 5 years, after 10 years 87% of these patients are still recognized as excellent or good function with an average of 41.9, 83% got an excellent or good score with an average of 40.7 after twenty years.<sup>5</sup>

### LR0I

The LROI uses NRS (rest), NRS (activity), EQ5D index score, EQ5D thermometer, HOOS-PS score, Oxford Hip score, Anchor question: Daily functioning to measure PROMs for patients underwent hip arthroplasty procedures. According to the LROI, the response rate of pre-operative PROMs achieved 66.7% in 2022. The response rate of all three preoperative, 3 and 12 months postoperative in 2021 achieved 35.7%.7

38 | 52

Published by CeramTec GmbH CeramTec-Platz 1–9 | 73207 Plochingen, Germany Phone: +49 7153 611-513 ceranews@ceramtec.de | www.ceranews.com Stuttgart district court commercial register, no. 734826 VAT identification no. DE814031115

Concept and Editing: Florence Petkow, Dr. Alessandro Alan Porporati Design and Production: Fiona Lennartz

CeramTec is committed to selecting and bringing to inter-ested parties relevant articles on bioceramics related topics. The presented authors' views and opinions are solely those of the authors of these publications. It is the focus and intent of CeraNews that CeramTec presents and comments on the authors' views and opinions in a specific context. Such comments and editorials therefore solely express CeramTec's views and opinions and not necessarily those of the quoted authors.

All statements are provided for educational purposes. For product, safety, and risk information, always refer to the labeling of the legal manufacturer.



Conventional femoral BIOLOX® *delta* heads and inserts as well as BIOLOX®OPTION products are registered by CeramTec's customers. Products are not registered / available in all



(in) 🖂 🌐

(in) 🖂 🌐

### **Current Trends and Recent Publications** (since 2023)

### **Dual mobility**

In all analyzed registries, the use of dual mobility bearings has steadily increased over the years. The NJR confirms that the CoPoM dual mobility bearings show lower revision than the MoPoM combinations, but with no significant difference.

### Resurfacing

Metal resurfacing is still restricted to a carefully monitored patient selection. Women are mostly excluded from this procedure. Ceramic resurfacing procedures are recorded by the NJR and AOA NJRR.

Revision rate of CoC resurfacing is recorded by the NJR for the first time in 2022, although this construct is still undergone in small numbers (N=249). The early revision rate at 1 year for CoC resurfacing is similar to that for MoM resurfacing (1.27% (0.41%-3.87%) vs. 1.18% (1.08%-1.29%)), and lower at 3 years (1.91% (0.71%-5.11%) vs. 2.90% (2.74%-3.06%)) and 5 years (1.91% (0.71%-5.11%) vs. 5.06% (4.85%-5.28%)).

The revision rate (at 1 year) of the MatOrtho ReCerf<sup>®</sup> CoC resurfacing has been reported for the first time by the AOA NJRR in 2020. In 2022, 42 new procedures have been reported. The Australian Registry showed that the revision rate at 1 year of MatOrtho ReCerf<sup>®</sup> CoC resurfacing (0.3% (0.0%, 2.1%)) and at 3 years (0.3% (0.0%, 2.1%)), with only 1 revision of all 346 procedures, was lower than other MoM resurfacing.

### **New Publications**

The following is a list of newly registry-based publications found on PubMed since 2023.

### 😹 NJR

1. Orce Rodríguez A, Smith PN, Johnson P, O'Sullivan M, Holder C, Shimmin A. registrybased study of survivorship of cemented femoral components versus collared cementless femoral components in total hip arthroplasty in older patients with osteoarthritis. *Bone Joint J.* 2024;106-B(3 Supple A):121-129. doi:10.1302/0301-620X.106B3.BJJ-2023-0771.R1.

2. Paoli E, Bergadano D, Sheng S, Pandit H. National Registry data analysis on a unique highly-crosslinked polyethylene for total hip arthroplasty. *Arthroplast Today*. 2023;24:101267. doi:10.1016/j.artd.2023.101267.

3. Subbiah Ponniah H, Logishetty K, Edwards TC, Singer GC. Survivorship and risk factors for revision of metal-on-metal hip resurfacing. *Bone Jt Open*. 2023;4(11):853-858. doi:10.1302/2633-1462.411.BJO-2023-0084.R1.

39 | 52

Published by Ceram Tec GmbH Ceram Tec-Platz 1–9 | 73207 Plochingen, Germany Phone: +49 7153 611-513 ceranews@ceramtec.de | www.ceranews.com Stuttgart district court commercial register, no. 734826

VAT identification no. DE814031115

Responsible Editor: Dr. Henrich Mannel Concept and Editing: Florence Petkow, Dr. Alessandro Alan Porporati Design and Production: Fiona Lennartz

MD-IPM-00753 Version 1.0, August 2024

CeramTec is committed to selecting and bringing to interested parties relevant articles on bioceramics related topics. The presented authors' views and opinions are solely those of the authors of these publications. It is the focus and intent of CeraNews that CeramTec presents and comments on the authors' views and opinions in a specific context. Such comments and editorials therefore solely express CeramTec's views and opinions and not necessarily those of the quoted authors.

All statements are provided for educational purposes. For product, safety, and risk information, always refer to the labeling of the legal manufacturer. Ceramic experts

Conventional femoral BIOLOX® *delta* heads and inserts as well as BIOLOX®OPTION products are registered by CeramTec's customers. Products are not registered / available in all countries.

BIOLOX® delta, BIOLOX® OPTION, BIOLOX® and CeramTec are registered trademarks of the CeramTec Group, Germany. MatOrtho® and ReCerf® are trademarks of MatOrtho Limited. H® is a trademark of Embody Orthopaedic Limited.

©CeramTec GmbH 2024. All rights reserved.

4. Sabah SA, Knight R, Nicolson PJA, et al. Epidemiology of revision hip replacement surgery in the UK over the past 15 years-an analysis from the National Joint Registry. *BMJ Open.* 2023;13(10):e072462. doi:10.1136/bmjopen-2023-072462.

5. Holleyman RJ, Jameson SS, Reed M, et al. Consultant revision hip arthroplasty volumes and new consultant volume trajectories in England, Wales, Northern Ireland, and the Isle of Man. *Bone Joint* J. 2023;105-B(10):1060-1069. doi:10.1302/0301-620X.105B10.BJJ-2023-0311.R1.

6. McLaughlin J, Kipping R, Owen-Smith A, et al. What effect have commissioners' policies for body mass index had on hip replacement surgery?: an interrupted time series analysis from the National Joint Registry for England. *BMC Med.* 2023;21(1):202. doi:10.1186/s12916-023-02899-3.

7. Lenguerrand E, Whitehouse MR, Beswick AD, et al. Mortality and re-revision following single-stage and two-stage revision surgery for the management of infected primary hip arthroplasty in England and Wales. *Bone Joint Res.* 2023;12(5):321-330. doi:10.1302/2046-3758.125.BJR-2022-0131.R1.

8. Lenguerrand E, Ben-Shlomo Y, Rangan A, et al. Inequalities in provision of hip and knee replacement surgery for osteoarthritis by age, sex, and social deprivation in England between 2007-2017: a population-based cohort study of the National Joint Registry. *PLoS Med.* 2023;20(4):e1004210. doi:10.1371/journal.pmed.1004210.

9. Singhal R, Leong JW, Rajpura A, Porter ML, Board TN. National Joint Registry recorded untoward intraoperative events during primary total hip arthroplasty: an investigation into the data accuracy, causal mechanisms and attributability. *Ann R Coll Surg Engl.* 2023;105(2):150-156. doi:10.1308/rcsann.2021.0281.

10. Hastie GR, Asle SG, Gambhir A, Board TN. Revision of double-tapered, titanium, fully hydroxyapatite-coated femoral stems: ease of extraction and subsequent reconstruction. *Hip Int.* 2023;33(3):485-489. doi:10.1177/11207000211069774.

### 🛅 AOA NJRR

11. Ackerman IN, Berkovic D, Soh SE, et al. Stakeholder perspectives on short-stay joint replacement programs: results from a national cross-sectional study. *BMC Health Serv Res.* 2023;23(1):1436. doi:10.1186/s12913-023-10427-5.

12. Ghadirinejad K, Graves S, de Steiger R, et al. What is the most appropriate comparator group to use in assessing the performance of primary total hip prostheses within the community?. *Hip Int*. doi:10.1177/11207000231216708.

13. Vercruysse LYG, Milne LP, Harries DTC, de Steiger RN, Wall CJ. Lower revision rates and improved stability with a monoblock ceramic acetabular cup. *J Arthroplasty*. doi:10.1016/j.arth.2023.10.032.

40 | 52

Published by CeramTec GmbH CeramTec-Platz 1–9 | 73207 Plochingen, Germany Phone: +49 7153 611-513 ceranews@ceramtec.de | www.ceranews.com Stuttgart district court commercial register, no. 734826

VAT identification no. DE814031115

Responsible Editor: Dr. Henrich Mannel Concept and Editing: Florence Petkow, Dr. Alessandro Alan Porporati Design and Production: Fiona Lennartz

MD-IPM-00753 Version 1.0, August 2024

CeramTec is committed to selecting and bringing to interested parties relevant articles on bioceramics related topics. The presented authors' views and opinions are solely those of the authors of these publications. It is the focus and intent of CeraNews that CeramTec presents and comments on the authors' views and opinions in a specific context. Such comments and editorials therefore solely express CeramTec's views and opinions and not necessarily those of the quoted authors.

All statements are provided for educational purposes. For product, safety, and risk information, always refer to the labeling of the legal manufacturer. THE CERANIC EXPERTS Conventional femoral BIOLOX® *delta* heads and inserts as well as BIOLOX®OPTION products are registered by CeramTec's customers. Products are not registered / available in all

BIOLOX<sup>®</sup>delta, BIOLOX<sup>®</sup>OPTION, BIOLOX<sup>®</sup> and CeramTec are registered trademarks of the CeramTec Group, Germany. MatOrtho<sup>®</sup> and ReCert<sup>®</sup> are trademarks of MatOrtho Limited.

©CeramTec GmbH 2024. All rights reserved

1|2024

14. Van Veghel MHW, Hannink G, Lewis PL, Holder C, Van Steenbergen LN, Schreurs BW. Short-stem hip arthroplasty in Australia and the Netherlands: a comparison of 12,680 cases between the Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR) and the Dutch Arthroplasty Register (LROI). Acta Orthop. 2023;94:453-459. doi:10.2340/17453674.2023.18491.

15. Tierney J, Jackman E, Holder C, Wall CJ, Wilson CJ. Increased rates of late periprosthetic fractures in larger hydroxyapatite-coated cementless stems: are collared stems a better alternative for total hip arthroplasty?. J Arthroplasty. 2024;39(3):744-749. doi:10.1016/j.arth.2023.08.068.

16. Tyas B, Marsh M, de Steiger R, et al. Long-term implant survival following hemiarthroplasty for fractured neck of femur. Bone Joint J. 2023;105-B(8):864-871. doi:10.1302/0301-620X.105B8.BJJ-2022-1150.R3.

17. Hoskins W, Bingham R, Corfield S, Harries D, Harris IA, Vince KG. Do the revision rates of arthroplasty surgeons correlate with postoperative patient-reported outcome measure scores? A study from the Australian Orthopaedic Association National Joint Replacement Registry. Clin Orthop Relat Res. doi:10.1097/CORR.00000000002737.

18. Truong AP, Wall CJ, Stoney JD, Graves SE, Lorimer MF, de Steiger RN. Obesity is associated with an increased risk of undergoing hip replacement in Australia. ANZ J Surg. 2023;93(7-8):1901-1906. doi:10.1111/ans.18543.

19. Mulford JS, Ackerman I, Holder C, Cashman KS, Graves SE, Harris IA. The association between body mass index and patient-reported outcome measures before and after primary total hip or knee arthroplasty: a registry. ANZ J Surg. 2023;93(6):1665-1673. doi:10.1111/ans.18449.

20. Wall CJ, de Steiger RN, Mulford JS, Lewis PL, Campbell DG. Perception of perioperative risk for arthroplasty patients: a poll of Australian Orthopedic Surgeons. J Arthroplasty. 2023;38(8):1418-1422. doi:10.1016/j.arth.2023.02.056.

21. Harris IA, Lorimer MF, Davies CE, et al. Hip arthroplasty outcomes in the presence of kidney failure: a national data linkage study. J Arthroplasty. 2023;38(7):1295-1302. doi:10.1016/j.arth.2023.01.014.

### EPRD

22. de Steiger RN, Hallstrom BR, Lübbeke A, Paxton EW, van Steenbergen LN, Wilkinson M. Identification of implant outliers in joint replacement registries. EFORT Open Rev. 2023;8(1):11-17. doi:10.1530/EOR-22-0058.

### 41 | 52

Published by CeramTec GmbH CeramTec-Platz 1–9 | 73207 Plochingen, Germany Phone: +49 7153 611-513 ranews@ceramtec.de | www.ceranews.com uttgart district court commercial register, no. 734826

Concept and Editing: Florence Petkow, Dr. Alessandro Alan Porporati Design and Production: Fiona Lennartz

CeramTec is committed to selecting and bringing to inter-ested parties relevant articles on bioceramics related topics. The presented authors' views and opinions are solely those of the authors of these publications. It is the focus and intent of CeraNews that CeramTec presents and comments on the authors' views and opinions in a specific context. Such comments and editorials therefore solely express CeramTec's views and opinions and not necessarily those of the quoted authors

All statements are provided for educational purposes. For product, safety, and risk information, always refer to the labeling of the legal manufacturer.

Conventional femoral BIOLOX® *delta* heads and inserts as well as BIOLOX® OPTION products are registered by CeramTec's customers. Products are not registered / available in all

in 🖂 🌐

23. de Steiger RN, Pratt NL, Gulyani A, et al. Antibiotic utilisation in primary and revision total hip replacement patients: a registry linkage cohort study of 106 253 patients using the Australian Orthopaedic Association National Joint Replacement Registry. Pharmacoepidemiol Drug Saf. 2023;32(2):238-247. doi:10.1002/pds.5522.

24. Thomsen M, van Uden M, Kretzer JP. Aktuelles Design und Zementmanteldicke in der Hüftendoprothetik: Theorie und Analyse der Registerdaten [Current design and cement mantle thickness in hip arthroplasty: theory and analysis of register data]. Orthopadie (Heidelb). 2024;53(1):1-10. doi:10.1007/s00132-023-04454-7.

25. Leopold VJ, Krull P, Hardt S, et al. Is elective total hip arthroplasty safe in nonagenarians?: an arthroplasty registry analysis. J Bone Joint Surg Am. 2023;105(20):1583-1593. doi:10.2106/JBJS.23.00092.

26. Szymski D, Walter N, Krull P, et al. Comparison of mortality rate and septic and aseptic revisions in total hip arthroplasties for osteoarthritis and femoral neck fracture: an analysis of the German Arthroplasty Registry. J Orthop Traumatol. 2023;24(1):29. doi:10.1186/s10195-023-00711-9.

27. Grimberg AW, Steinbrück A. 10 Jahre Endoprothesenregister Deutschland (EPRD): was wurde erreicht? [10 years of the German Arthroplasty Registry-EPRD: what has been achieved?]. Orthopadie (Heidelb). 2023;52(6):463-471. doi:10.1007/s00132-023-04385-3.

28. Szymski D, Walter N, Krull P, et al. Infection after intracapsular femoral neck fracture does antibiotic-loaded bone cement reduce infection risk after hemiarthroplasty and total hip arthroplasty?. Bone Joint Res. 2023;12(5):331-338. doi:10.1302/2046-3758.125.BJR-2022-0314.R1.

29. Szymski D, Walter N, Krull P, et al. The prophylactic effect of single vs. dual antibioticloaded bone cement against periprosthetic joint infection following hip arthroplasty for femoral neck fracture: an analysis of the German Arthroplasty Registry. Antibiotics (Basel). 2023;12(4):732. doi:10.3390/antibiotics12040732.

30. Osmanski-Zenk K, Klinder A, Malzahn J, et al. 3-Jahres-Revisionsrate von zertifizierten EndoProthetikZentren nach EndoCert: Risikoadjustierte Analyse der Ergebnisqualität und Vergleich mit anderen Qualitätssicherungssystemen [Three-year revision rate of certified centres for joint replacement according to EndoCert: risk-adjusted analysis of outcome quality and comparison with other quality assurance systems]. Orthopadie (Heidelb). 2023;52(4):320-331. doi:10.1007/s00132-023-04360-y.

31. Krull P, Steinbrück A, Grimberg AW, Melsheimer O, Morlock M, Perka C. Standard- und Spezialinlays in primärer Hüftendoprothetik: Aktuelle Studien- und Umfrageergebnisse aus dem Endoprothesenregister Deutschland (EPRD) [Standard and special liner in primary hip arthroplasty: current study and survey results from the German Arthroplasty Registry (EPRD)]. Orthopadie (Heidelb). 2023;52(3):222-232. doi:10.1007/s00132-022-04333-7.

Published by Ceram Tec GmbH Ceram Tec-Platz 1–9 | 73207 Plochingen, Germany Phone: +49 7153 611-513 ceranews@ceramtec.de | www.ceranews.com Stuttgart district court commercial register, no. 734826

Concept and Editing: Florence Petkow, Dr. Alessandro Alan Porporati Design and Production: Fiona Lennartz

Ceram iec is committed to selecting and bringing to inter-ested parties relevant articles on bioceramics related topics. The presented authors' views and opinions are solely those of the authors of these publications. It is the focus and intent of CeraNews that CeramTec presents and comments on the authors' views and opinions in a specific context. Such comments and editorials therefore solely express CeramTec's views and opinions and not necessarily those of the quoted euthors.

All statements are provided for educational purposes. For product, safety, and risk information, always refer to the labeling of the legal manufacturer.

Conventional femoral BIOLOX® *delta* heads and inserts as well as BIOLOX® OPTION products are registered by CeramTec's customers. Products are not registered / available in all

(in) 🖂 🌐

### AJRR 📕

32. Springer BD, Mullen K, Donnelly P, Tucker K, Caton E, Huddleston J. Is American Joint Replacement Registry data consistent with international survivorship in Hip and Knee Arthroplasty? A comparative analysis. *J Arthroplasty*. doi:10.1016/j.arth.2024.02.055.

33. Kelly M, Chen AF, Ryan SP, et al. Femoral component design is associated with the risk of periprosthetic femur fracture after cementless THA in patients 65 years or older. *Clin Orthop Relat Res.* doi:10.1097/CORR.0000000002985.

34. Carender CN, Gulley ML, De A, Bozic KJ, Callaghan JJ, Bedard NA. Outcomes vary significantly using a tiered approach to define success after total hip arthroplasty. *Iowa Orthop J.* 2023;43(1):45-54.

35. Otero JE, Heckmann ND, Jaffri H, et al. Dual mobility articulation in revision total hip arthroplasty: an American Joint Replacement Registry Analysis of patients aged 65 years and older. *J Arthroplasty*. 2023;38(7 Suppl 2):S376-S380. doi:10.1016/j.arth.2023.05.023.

36. Ackerman SJ, Vigdorchik JM, Siljander BR, Gililland JM, Sculco PK, Polly DW. Projected savings associated with lowering the risk of total hip arthroplasty revision due to dislocation in patients with spinopelvic pathology. *Clinicoecon Outcomes Res.* 2023;15:321-330. doi:10.2147/CEOR.S410453.

37. Kelly M, Chen AF, Ryan SP, et al. Cemented femoral fixation in total hip arthroplasty reduces the risk of periprosthetic femur fracture in patients 65 years and older: an analysis from the American Joint Replacement Registry. *J Arthroplasty.* 2023;38(7 Suppl 2):S351-S354. doi:10.1016/j.arth.2023.04.039.

38. Coombs S, Oakley CT, Buehring W, Arraut J, Schwarzkopf R, Rozell JC. Hospital teaching status and patient-reported outcomes following primary total hip arthroplasty: an American Joint Replacement Registry study. *J Arthroplasty.* 2023;38(7 Suppl 2):S289-S293. doi:10.1016/j.arth.2023.04.022.

39. Wilson JM, Broida SE, Kremers HM, et al. Can the American Joint Replacement Registry utilize administrative claims data to accurately classify revision total hip arthroplasty (THA) surgical diagnoses?. *J Arthroplasty*. 2023;38(7S):S179-S183.e2. doi:10.1016/j.arth.2023.04.021.

40. Cieremans D, Shah A, Slover J, Schwarzkopf R, Meftah M. Trends in complications and outcomes in patients aged 65 years and younger undergoing total hip arthroplasty: data from the American Joint Replacement Registry. *J Am Acad Orthop Surg Glob Res Rev.* 2023;7(3):e22.00256. doi:10.5435/JAAOSGlobal-D-22-00256.

### 43 | 52

Published by CeramTec GmbH CeramTec-Platz 1–9 | 73207 Plochingen, Germany Phone: +49 7153 611-513 ceranews@ceramtec.de | www.ceranews.com Stuttgart district court commercial register, no. 734826

Stuttgårt district court commercial register, no. 734826 VAT identification no. DE814031115

Responsible Editor: Dr. Henrich Mannel Concept and Editing: Florence Petkow, Dr. Alessandro Alan Porporati Design and Production: Fiona Lennartz

MD-IPM-00753 Version 1.0, August 2024

CeramTec is committed to selecting and bringing to interested parties relevant articles on bioceramics related topics. The presented authors' views and opinions are solely those of the authors of these publications. It is the focus and intent of CeraNews that CeramTec presents and comments on the authors' views and opinions in a specific context. Such comments and editorials therefore solely express CeramTec's views and opinions and not necessarily those of the quoted authors.

All statements are provided for educational purposes. For product, safety, and risk information, always refer to the labeling of the legal manufacturer. Conventional femoral BIOLOX® delta heads and inserts as well as BIOLOX®OPTION products are registered by CeramTec's customers. Products are not registered / available in all countries

BIOLOX<sup>®</sup>delta, BIOLOX<sup>®</sup>OPTION, BIOLOX<sup>®</sup> and CeramTec are registered trademarks of the CeramTec Group, Germany. MatOrtho<sup>®</sup> and ReCerf<sup>®</sup> are trademarks of MatOrtho Limited. H1<sup>®</sup> is a trademark of Embody Orthopaedic Limited.

©CeramTec GmbH 2024. All rights reserved.

1|2024

41. Nessler JM, Malkani AL, Yep PJ, Mullen KJ, Illgen RL 2nd. Dislocation rates of primary total hip arthroplasty in patients with prior lumbar spine fusion and lumbar degenerative disk disease with and without utilization of dual mobility cups: an American Joint Replacement Registry study. J Am Acad Orthop Surg. 2023;31(5):e271-e277. doi:10.5435/JAAOS-D-22-00767.

42. Oakley CT, Arraut J, Lygrisse K, Schwarzkopf R, Slover JD, Rozell JC. The effect of surgeon and hospital volume on total hip arthroplasty patient-reported outcome measures: an American Joint Replacement Registry study. J Am Acad Orthop Surg. 2023;31(4):205-211. doi:10.5435/JAAOS-D-22-00525.

### 📉 NZJR

43. English RT, Munro JT, Monk AP. Increasing femoral head size from 32 mm to 36 mm does not increase the revision risk for total hip replacement: a New Zealand joint registry study. Hip Int. 2024;34(1):66-73. doi:10.1177/11207000231210487.

44. Lingard MCH, Willis J, Frampton CMA, Hooper GJ. Survey of New Zealand arthroplasty surgeons on surgeon-level outcome reporting. J Arthroplasty. 2023;38(11):2254-2258. doi:10.1016/j.arth.2023.05.069.

45. Boyle AB, Zhu M, Frampton C, Poutawera V, Vane A. Comparing modern uncemented, hybrid and cemented implant combinations in older patients undergoing primary total hip arthroplasty, a New Zealand Joint Registry study. Arch Orthop Trauma Surg. 2023;143(6):3597-3604. doi:10.1007/s00402-022-04610-2.

46. Foxall-Smith M, Wyatt MC, Frampton C, Kieser D, Hooper G. The 45-year evolution of the Mathys RM monoblock cups: have the paradigm shifts been worthwhile?. Hip Int. 2023;33(2):193-202. doi:10.1177/11207000211067507.

#### SAR

47. Wolf O, Ghukasyan Lakic T, Ljungdahl J, et al. Reoperation-free survival after hip screws or hip arthroplasty for undisplaced femoral neck fractures in the elderly. Bone Jt Open. 2024;5(2):87-93. doi:10.1302/2633-1462.52.BJO-2023-0143.R1.

48. Cnudde PHJ, Nåtman J, Rolfson O, Hailer NP. The true dislocation incidence following elective total hip replacement in Sweden: how does it relate to the revision rate?. J Clin Med. 2024;13(2):598. doi:10.3390/jcm13020598.

49. Enequist T, Persson L, Kojer E, Gunnarsson L, Gerdhem P. Spinal surgery and the risk of reoperation after total hip arthroplasty: a cohort study based on Swedish spine and hip arthroplasty registers. Acta Orthop. 2024;95:25-31. doi:10.2340/17453674.2024.35228.

44 | 52

Published by CeramTec GmbH CeramTec-Platz 1–9 | 73207 Plochingen, Germany Phone: +49 7153 611-513 ranews@ceramtec.de | www.ceranews.com uttgart district court commercial register, no. 734826

Dr. Alessandro Alan Porporati Design and Production: Fiona Lennartz

CeramTec is committed to selecting and bringing to inter-ested parties relevant articles on bioceramics related topics. The presented authors' views and opinions are solely those of the authors of these publications. It is the focus and intent of CeraNews that CeramTec presents and comments on the authors' views and opinions in a specific context. Such comments and editorials therefore solely express CeramTec's views and opinions and not necessarily those of the quoted authors

All statements are provided for educational purposes. For product, safety, and risk information, always refer to the labeling of the legal manufacturer.

Conventional femoral BIOLOX®*delta* heads and inserts as wel as BIOLOX®OPTION products are registered by CeramTec's customers. Products are not registered / available in all

(in) 🖂 🌐

1|2024

### (in) 🖂 🌐

50. Lagergren J, Strøm Rönnquist S, Wolf O, et al. The different strategies in treating displaced femoral neck fractures: mid-term surgical outcome in a register-based cohort of 1,283 patients aged 60-69 years. Acta Orthop. 2023;94:505-510. doi:10.2340/1745367 4.2023.20284.

51. Persson A, Sköldenberg O, Mohaddes M, Eisler T, Gordon M. Increased mortality after total hip prosthetic joint infection is mainly caused by the comorbidities rather than the infection itself. Acta Orthop. 2023;94:484-489. doi:10.2340/17453674.2023.18619.

52. Schaufelberger M, Rolfson O, Kärrholm J. Outcome of patients with osteoarthritis aged 90 to 101 years after cemented total hip arthroplasty: 1,385 patients from the Swedish Arthroplasty Register. Acta Orthop. 2023;94:477-483. doi:10.2340/17453674.20 23.18656.

53. Sattar A, Kärrholm J, Möller M, Chatziagorou G. Fracture pattern and risk factors for reoperation after treatment of 156 periprosthetic fractures around an anatomic cemented hip stem. Acta Orthop. 2023;94:438-446. doi:10.2340/17453674.2023.18263.

54. Dale H, Fenstad AM, Hallan G, et al. Increasing risk of revision due to infection after primary total hip arthroplasty: results from the Nordic Arthroplasty Register Association. Acta Orthop. 2023;94:307-315. doi:10.2340/17453674.2023.13648.

55. Mikkelsen RT, Overgaard S, Pedersen AB, et al. Does choice of bearings influence the survival of cementless total hip arthroplasty in patients aged 20-55 years? Comparison of 21,594 patients reported to the Nordic Arthroplasty Register Association dataset 2005-2017. Acta Orthop. 2023;94:266-273. doi:10.2340/17453674.2023.13384.

56. Cornell CN. CORR Insights®: What is the role of stem size and offset in the risk of nonseptic revision of the Exeter® 150-mm stem? A study from the Swedish Arthroplasty Register. Clin Orthop Relat Res. 2023;481(9):1700-1702. doi:10.1097/ CORR.00000000002708.

57. Gustafsson K, Kvist J, Eriksson M, Rolfson O. What factors identified in initial osteoarthritis management are associated with poor patient-reported outcomes after THA? A register-based study. Clin Orthop Relat Res. 2023;481(9):1732-1742. doi:10.1097/ CORR.00000000002681.

58. Jolbäck P, Bedeschi Rego De Mattos C, Rogmark C, Chen AF, Nauclér E, Tsikandylakis G. Patient-reported outcomes after primary total hip arthroplasty are not affected by the sex of the surgeon: a register-based study of 8,383 procedures in western Sweden. J Am Acad Orthop Surg. 2023;31(13):692-700. doi:10.5435/JAAOS-D-22-00840.

59. Teni FS, Burström K, Devlin N, Parkin D, Rolfson O; Swedish Quality Register (SWEQR) Study Group. Experience-based health state valuation using the EQ VAS: a register-based study of the EQ-5D-3L among nine patient groups in Sweden. Health Qual Life Outcomes. 2023;21(1):34. doi:10.1186/s12955-023-02115-z.

45 | 52

Published by Ceram Tec GmbH Ceram Tec-Platz 1–9 | 73207 Plochingen, Germany Phone: +49 7153 611-513 ceranews@ceramtec.de | www.ceranews.com Stuttgart district court commercial register, no. 734826

Concept and Editing: Florence Petkow, Dr. Alessandro Alan Porporati Design and Production: Fiona Lennartz

CeramTec is committed to selecting and bringing to inter-ested parties relevant articles on bioceramics related topics. The presented authors' views and opinions are solely those of the authors of these publications. It is the focus and intent of CeraNews that CeramTec presents and comments on the authors' views and opinions in a specific context. Such comments and editorials therefore solely express CeramTec's views and opinions and not necessarily those of the quoted authors

All statements are provided for educational purposes. For product, safety, and risk information, always refer to the labeling of the legal manufacturer.

Conventional femoral BIOLOX® *delta* heads and inserts as well as BIOLOX® OPTION products are registered by CeramTec's customers. Products are not registered / available in all

### LROI

60. Bongers J, Belt M, Spekenbrink-Spooren A, Smulders K, Schreurs BW, Koeter S. Smoking is associated with higher short-term risk of revision and mortality following primary hip or knee arthroplasty: a cohort study of 272,640 patients from the Dutch Arthroplasty Registry. *Acta Orthop.* 2024;95:114-120. doi:10.2340/17453674.2024.39966.

61. Rietbergen L, Dooren BV, Zijlstra WP, et al. The rise of the direct anterior approach: trends, learning curves, and patient characteristics of 63,182 primary total hip arthroplasties in the Dutch Arthroplasty Register (LROI). *J Arthroplasty*. doi:10.1016/j. arth.2024.01.017.

62. van Veghel MHW, Belt M, Spekenbrink-Spooren A, et al. Validation of the incidence of reported periprosthetic joint infections in total hip and knee arthroplasty in the Dutch Arthroplasty Register. *J Arthroplasty*. doi:10.1016/j.arth.2023.10.040.

63. Bos PK, Spekenbrink-Spooren A, Croughs P, Bierma-Zeinstra SMA, Reijman M, Van Oldenrijk J. Risk for re-revision and type of antibiotic-loaded bone cement in hip or knee arthroplasty revisions: report of the Dutch Arthroplasty Register. *Acta Orthop.* 2023;94:471-476. doi:10.2340/17453674.2023.18645.

64. Schmitz PP, Hannink G, Somford MP, Schreurs BW, Van Susante JLC. Revision risk of salvage compared with acute total hip arthroplasty following femoral neck fracture: an analysis from the Dutch Arthroplasty Register. *Acta Orthop.* 2023;94:399-403. doi:10.234 0/17453674.2023.17743.

65. Bonsel JM, Reijman M, Verhaar JAN, van Steenbergen LN, Janssen MF, Bonsel GJ. Socioeconomic inequalities in patient-reported outcome measures of Dutch primary hip and knee arthroplasty patients for osteoarthritis. *Osteoarthritis Cartilage*. 2024;32(2):200-209. doi:10.1016/j.joca.2023.07.004.

66. Van Veghel MHW, Hannink G, Van Oldenrijk J, Van Steenbergen LN, Schreurs BW. A comparison of uncemented short versus standard stem length in total hip arthroplasty: results from the Dutch Arthroplasty Register. *Acta Orthop.* 2023;94:330-335. doi:10.2340/17453674.2023.13652.

67. Van Dooren B, Peters RM, Jutte PC, Stevens M, Schreurs BW, Zijlstra WP. Similar revision rate after cemented and cementless femoral revisions for periprosthetic femoral fractures in total hip arthroplasty: analysis of 1,879 revision hip arthroplasties in the Dutch Arthroplasty Register. *Acta Orthop.* 2023;94:260-265. doi:10.2340/17453674.2023.13211.

68. Van Dooren B, Peters RM, Ettema HB, et al. Revision risk by using the direct superior approach (DSA) for total hip arthroplasty compared with postero-lateral approach: early nationwide results from the Dutch Arthroplasty Register (LROI). *Acta Orthop.* 2023;94:158-164. doi:10.2340/17453674.2023.11959.

46 | 52

Published by CeramTec GmbH CeramTec-Platz 1–9 | 73207 Plochingen, Germany Phone: +49 7153 611-513 ceranews@ceramtec.de | www.ceranews.com Stuttgart district court commercial register, no. 734826

VAT identification no. DE814031115

Responsible Editor: Dr. Henrich Mannel Concept and Editing: Florence Petkow, Dr. Alessandro Alan Porporati Design and Production: Fiona Lennartz

MD-IPM-00753 Version 1.0, August 2024

CeramTec is committed to selecting and bringing to interested parties relevant articles on bioceramics related topics. The presented authors' views and opinions are solely those of the authors of these publications. It is the focus and intent of CeraNews that CeramTec presents and comments on the authors' views and opinions in a specific context. Such comments and editorials therefore solely express CeramTec's views and opinions and not necessarily those of the quoted authors.

All statements are provided for educational purposes. For product, safety, and risk information, always refer to the labeling of the legal manufacturer.

Conventional femoral BIOLOX®*delta* heads and inserts as well as BIOLOX®OPTION products are registered by CeramTec's customers. Products are not registered / available in all countries.

BIOLOX<sup>®</sup>delta, BIOLOX<sup>®</sup>OPTION, BIOLOX<sup>®</sup> and CeramTec are registered trademarks of the CeramTec Group, Germany. MatOrtho<sup>®</sup> and ReCerf<sup>®</sup> are trademarks of MatOrtho Limited. H1<sup>®</sup> is a trademark of Embody Orthopaedic Limited.

©CeramTec GmbH 2024. All rights reserved.

1|2024

69. van Steenbergen LN, de Reus IM, Hannink G, Vehmeijer SB, Schreurs BW, Zijlstra WP. Femoral head size and surgical approach affect dislocation and overall revision rates in total hip arthroplasty: up to 9-year follow-up data of 269,280 procedures in the Dutch Arthroplasty Register (LROI). *Hip Int.* 2023;33(6):1056-1062. doi:10.1177/11207000231160223.

70. van Brug HE, Rosendaal FR, van Steenbergen LN, Nelissen RGHH, Gademan MGJ. Data linkage of two national databases: Lessons learned from linking the Dutch Arthroplasty Register with the Dutch Foundation for Pharmaceutical Statistics. *PLoS One.* 2023;18(3):e0282519. doi:10.1371/journal.pone.0282519.

71. van Loon J, Sierevelt IN, Spekenbrink-Spooren A, et al. Higher risk of 2-year cup revision of ceramic-on-ceramic versus ceramic-on-polyethylene bearing: analysis of 33,454 primary press-fit total hip arthroplasties registered in the Dutch Arthroplasty Register (LROI). *Hip Int.* 2023;33(2):280-287. doi:10.1177/11207000211064975.

72. Kuijpers MF, Hannink G, van Steenbergen LN, Schreurs BW. A significant change towards cemented fixation in revision total hip arthroplasty in patients younger than 55 years in the Netherlands: results of an observational cohort study in the Dutch Arthroplasty Register in 28,516 primary hip replacements and 1285 revision procedures. *Hip Int.* 2023;33(2):288-297. doi:10.1177/11207000211020002.

### New Registry-based Publications about THRs with Ceramic Bearings

### The following is short summary of new publications about ceramic bearings.

1. Vercruysse LYG, Milne LP, Harries DTC, de Steiger RN, Wall CJ. Lower revision rates and improved stability with a monoblock ceramic acetabular cup. *J Arthroplasty*. doi:10.1016/j.arth.2023.10.032.

This study investigates the survival rate and the reasons for revision of the DeltaMotion cup using data from the Australian Orthopedic National Joint Replacement Registry (AOANJRR) between 2001-2021. Monoblock ceramic/ceramic cups designed for LDHs have the potential to preserve acetabular bone stock, eliminating issues seen in metal-on-metal bearings.

Of 486,946 primary conventional THR procedures undertaken for any reasons, 4,033 used DeltaMotion cups and 482,913 were modular designs (107,758 CoC, 131,906 CoXLPE, 208,917 MoXLPE and 34,332 CMoXLPE). The result shows that the DeltaMotion cup had significantly lower cumulative percent revision compared to the modular bearings, also with a significantly lower revision rate for prosthetic dislocations and no revision for squeaking compared to other modular bearings. 175 ceramic breakages were recorded for the modular bearing group and only 1 ceramic breakage was recorded

47 | 52

Published by CeramTec GmbH CeramTec-Platz 1–9 | 73207 Plochingen, Germany Phone: +49 7153 611-513 ceranews@ceramtec.de | www.ceranews.com Stuttgart district court commercial register, no. 734826

VAT identification no. DE814031115

Responsible Editor: Dr. Henrich Mannel Concept and Editing: Florence Petkow, Dr. Alessandro Alan Porporati Design and Production: Fiona Lennartz

MD-IPM-00753 Version 1.0, August 2024

CeramTec is committed to selecting and bringing to interested parties relevant articles on bioceramics related topics. The presented authors' views and opinions are solely those of the authors of these publications. It is the focus and intent of CeraNews that CeramTec presents and comments on the authors' views and opinions in a specific context. Such comments and editorials therefore solely express CeramTec's views and opinions and not necessarily those of the quoted authors.

All statements are provided for educational purposes. For product, safety, and risk information, always refer to the labeling of the legal manufacturer.

Conventional femoral BIOLOX® *delta* heads and inserts as well as BIOLOX®OPTION products are registered by CeramTec's customers. Products are not registered / available in all countries.

BIOLOX<sup>®</sup>delta, BIOLOX<sup>®</sup>OPTION, BIOLOX<sup>®</sup> and CeramTec are registered trademarks of the CeramTec Group, Germany. MatOrtho<sup>®</sup> and ReCerf<sup>®</sup> are trademarks of MatOrtho Limited. H1<sup>®</sup> is a trademark of Embody Orthopaedic Limited.

(in) 🖂 🌐

### **OUTCOMES RESEARCH | REGISTRIES ANNUAL REPORTS 2023 IN REVIEW**

1 | 2024

for the DeltaMotion group. This study demonstrated that DeltaMotion cup is suitable for younger and more active patients based on their ongoing follow-up, although this cup is no longer manufactured.

2. van Loon J, Sierevelt IN, Spekenbrink-Spooren A, et al. Higher risk of 2-year cup revision of ceramic-on-ceramic versus ceramic-on-polyethylene bearing: analysis of 33,454 primary press-fit total hip arthroplasties registered in the Dutch Arthroplasty Register (LROI). *Hip Int.* 2023;33(2):280-287. doi:10.1177/11207000211064975.

This study describes 2-year cup revision rates of CoC and CoPE for primary press-fit THRs with one of the three most used cups recorded in the Dutch Arthroplasty Register (LROI) between 2007-2019. A total of 33,454 of press-fit THRs used one of the three most used cup types available with both CoC and CoPE bearing were included in this study, of which 12,535 were CoC and 20,919 were CoPE. The results showed that the overall 2-year cumulative cup revision rate was 0.53% (95%CI, 0.45-0.60). Overall, 84 THRs with CoC were revised at 2 years, a revision rate of 0.67% (95%CI, 0.54-0.81). CoPE had a total of 91 revisions with a revision rate of 0.44% (95%CI, 0.34-0.54). This result remained significant (HR 0.64 (95%CI, 0.44-0.93)) after adjusting for confounders (age, gender, cup type, head size) and CoPE was favored over CoC (p=0.019). In terms of revision reasons, cup revisions were only different because more cups were revised due to loosening (p=0.030) in the CoC (26.2% vs. 13.2%) compared to CoPE. There were 19 cases of cup revision due to aseptic loosening observed in CoC, with a revision rate of 0.153% (95%CI, 0.075-0.231). Revision rate of CoPE was 0.058% (95%CI, 0.019-0.097), with a total of 12 cup revisions for aseptic loosening.

48 | 52

Published by CeramTec GmbH CeramTec-Platz 1–9 | 73207 Plochingen, Germany Phone: +49 7153 611-513 ceranews@ceramtec.de | www.ceranews.com Stuttgart district court commercial register, no. 73482

VAT identification no. DE814031115 Responsible Editor: Dr. Henrich Mannel Concent and Edition: Elcrence Petkow

Concept and Editing: Florence Petkow, Dr. Alessandro Alan Porporati Design and Production: Fiona Lennartz

MD-IPM-00753 Version 1.0, August 2024

CeramTec is committed to selecting and bringing to interested parties relevant articles on bioceramics related topics. The presented authors' views and opinions are solely those of the authors of these publications. It is the focus and intent of CeraNews that CeramTec presents and comments on the authors' views and opinions in a specific context. Such comments and editorials therefore solely express CeramTec's views and opinions and not necessarily those of the quoted authors

All statements are provided for educational purposes. For product, safety, and risk information, always refer to the labeling of the legal manufacturer.



Conventional femoral BIOLOX® delta heads and inserts as well as BIOLOX® OPTION products are registered by CeramTec's customers. Products are not registered / available in all countries

BIOLOX<sup>®</sup>delta, BIOLOX<sup>®</sup>OPTION, BIOLOX<sup>®</sup> and CeramTec are registered trademarks of the CeramTec Group, Germany. MatOrtho<sup>®</sup> and ReCerf<sup>®</sup> are trademarks of MatOrtho Limited. H<sup>®</sup> is a trademark of Embody Orthopaedic Limited.

©CeramTec GmbH 2024. All rights reserved

### OUTCOMES RESEARCH | REGISTRIES ANNUAL REPORTS 2023 IN REVIEW

### in 🖂 🌐

1 | 2024

$\bigcap$	1.National Joint Registry. 20th Annual Report 2023. Surgical data to 31 December 2022. ISSN 2054-183X (Online). 2023:1-370.
	2.Smith PN, Gill DR, McAuliffe MJ, McDougall C, Stoney JD, Vertullo CJ, Wall CJ, Corfield S, Page R, Cuthbert AR, Du P, Harries D, Holder C, Lorimer MF, Cashman K, Lewis PL. Hip, Knee and Shoulder Arthroplasty: 2023 Annual Report, Australian Orthopaedic Association National Joint Replacement Registry, AOA: Adelaide, South Australia. 2023. https://doi.org/10.25310/YWQZ9375
	3.Endoprothesenregister Deutschland (EPRD). Jahresbericht 2023. Mit Sicherheit mehr Qualität. ISBN: 978-3- 949872-02-0. 2023:1-196.
	4.American Academy of Orthopaedic Surgeons (AAOS). American Joint Replacement Registry (AJRR): 2023 Annual Report. ISSN 2375-9119 (Online). 2023: 1-125.
	5. The New Zealand Joint Registry. Twenty-four Year Report January 1999 to December 2022. 2023:1-211.
	6.Swedish Arthroplasty Register. Annual report 2023. ISSN 16454-5982. 2023: 1-310.
	7.Dutch Arthroplasty Register (LROI). Online LROI annual report 2023. Joint arthroplasty data to 31 December 2022. 2023: 1-249.
	8. Endoprothesenregister Deutschland (EPRD). Statusbericht 2014 Mit Sicherheit mehr Qualität. 2015: 1-60.
	9.Endoprothesenregister Deutschland (EPRD). Jahresbericht 2015 Mit Sicherheit mehr Qualität. ISBN: 978-3- 9817673-1-5. 2016: 1-65.
	10. Endoprothesenregister Deutschland (EPRD). Jahresbericht 2016 Mit Sicherheit mehr Qualität. 2017: 1-64.
	11.Endoprothesenregister Deutschland (EPRD). Jahresbericht 2017 Mit Sicherheit mehr Qualität. ISBN: 978-3- 9817673-3-9. 2018: 1-80.
	12.German Arthroplasty Registry (EPRD). 2019 Annual Report. 2020: 1-125. doi:10.36186/reporteprd01202.
	13.Endoprothesenregister Deutschland (EPRD). Jahresbericht 2020 Mit Sicherheit mehr Qualität. 2020: 1-128. doi:10.36186/reporteprd022020.
	14.Endoprothesenregister Deutschland (EPRD). Jahresbericht 2021 Mit Sicherheit mehr Qualität. ISBN: 978-3- 9817673-9-1 2021: 1-193.
	15.Endoprothesenregister Deutschland (EPRD). Jahresbericht 2022. Mit Sicherheit mehr Qualität. ISBN: 978-3-

Published by CeramTec GmbH CeramTec-Platz 1–9 | 73207 Plochingen, Germany Phone: +49 7153 611-513 ceranews@ceramtec.de | www.ceranews.com Stuttgart district court commercial register, no. 734826 VAT identification no. DE814031115

949872-00-6 2022:1-175.

Responsible Editor: Dr. Henrich Mannel Concept and Editing: Florence Petkow, Dr. Alessandro Alan Porporati Design and Production: Fiona Lennartz

CeramTec is committed to selecting and bringing to inter-ested parties relevant articles on bioceramics related topics. The presented authors' views and opinions are solely those of the authors of these publications. It is the focus and intent of CeraNews that CeramTec presents and comments on the authors' views and opinions in a specific context. Such comments and editorials therefore solely express CeramTec's views and opinions and not necessarily those of the quoted authors.

All statements are provided for educational purposes. For product, safety, and risk information, always refer to the labeling of the legal manufacturer.

Conventional femoral BIOLOX®delta heads and inserts as well as BIOLOX®OPTION products are registered by CeramTec's customers. Products are not registered / available in all countries.

(in) 🖂 🌐

### **OUTCOMES RESEARCH | REGISTRIES ANNUAL REPORTS 2023 IN REVIEW**

### **Abbreviations, Tables and Figures**

AJRR: The American Joint Replacement Registry AOA NJRR: The Australian Orthopaedic Association National Joint Replacement Registry **CI:** Confidence Interval CMoP: Ceramicised Metal-on-Polyethylene CoC: Ceramic-on-Ceramic CoM: Ceramic-on-Metal CoP: Ceramic-on-Polyethylene (including both conventional polyethylene and cross-linked polyethylene) **CoPoM:** Ceramic-on-Polyethylene-on-Metal (Dual Mobility - only used by the NJR) **CoXLPE:** Ceramic-on-Cross-Linked Polyethylene CohXLPE: Ceramic-on-Highly Cross-Linked Polyethylene (only used by the EPRD) DM: Dual Mobility **EPRD:** Endoprothesenregister Deutschland (The German Arthroplasty Registry) EQ-5D: European Quality of Life 5 Dimensions EQ-5D-5L: European Quality of Life 5 Dimensions 5 Level Version EQ VAS Health: EuroQol-Visual Analogue Scales HOOS JR. Score: Hip Disability and Osteoarthritis Outcome Score for Joint Replacement Score HR: Hazard Ratio ISAR: International Society of Arthroplasty Registries MoM: Metal-on-Metal MoP: Metal-on-Polyethylene (including both conventional polyethylene and cross-linked polyethylene) MoPoM: Metal-on-Polyethylene-on-Metal (Dual Mobility - only used by the NJR) MoXLPE: Metal-on-Cross-Linked Polyethylene MohXLPE: Metal-on-Highly Cross-Linked Polyethylene (only used by the EPRD) NHS: The National Health Service

50 | 52

ublished by CeramTec GmbH eramTec-Platz 1–9 | 73207 Plochingen, Germany none: +49 7153 611-513 eranews@ceramtec.de | www.ceranews.com uttgart district court commercial register, no. 734826

Concept and Editing: Florence Petkow, Dr. Alessandro Alan Porporati Design and Production: Fiona Lennartz

CeramTec is committed to selecting and bringing to inter-ested parties relevant articles on bioceramics related topics. The presented authors' views and opinions are solely those of the authors of these publications. It is the focus and intent of CeraNews that CeramTec presents and comments on the authors' views and opinions in a specific context. Such comments and editorials therefore solely express CeramTec's views and opinions and not necessarily those of the quoted authors.

All statements are provided for educational purposes. For product, safety, and risk information, always refer to the labeling of the legal manufacturer.

Conventional femoral BIOLOX® *delta* heads and inserts as well as BIOLOX® OPTION products are registered by CeramTec's customers. Products are not registered / available in all

(in) 🖂 🌐

**OUTCOMES RESEARCH | REGISTRIES ANNUAL REPORTS 2023 IN REVIEW** 

### **Abbreviations, Tables and Figures**

NJR: The National Joint Registry, which covers England, Wales, Northern Ireland, the Isle of Man and the States of Guernsey

NZJR: The New Zealand Joint Registry

**OA:** Osteoarthritis

**PROMs:** Patient-Reported Outcome Measures

PROMIS-10: Patient-Reported Outcomes Measurement Information System-10

SAR: The Swedish Arthroplasty Register (Merger of the Swedish Hip Arthroplasty Register and the Swedish Knee Arthroplasty Register)

SD: Standard Deviation

THA: Total Hip Arthroplasty

THR: Total Hip Replacement

VR-12: The Veterans RAND 12 Item Health Survey

Figure 1a: Distribution of fixation methods in primary THRs in 2022 (Annual Data): in Australia, Germany, Netherlands as well as England, Wales, Northern Ireland, the Isle of Man and Guernsey.

Figure 1b: Distribution of femoral stem fixation methods in primary THRs (2012-2022) in the USA.

Figure 2a: Distribution of head sizes in primary THRs in 2022 (Annual Data): in Germany and Netherlands.

Figure 2b: Total Percentage of head sizes in primary THRs: in the United States and Netherlands.

Figure 3: Composition of femoral heads in primary THRs by year in England, Wales, Northern Ireland, the Isle of Man and Guernsey.

Figure 4: Composition of femoral heads in primary THRs by year in Germany.

Figure 5: Composition of femoral heads in primary THRs (2012-2022) in the United States.

Figure 6: Composition of femoral heads in primary THRs by year in the Netherlands.

Figure 7: CoP, MoP and CoC usage in primary THRs by year in England, Wales, Northern Ireland, the Isle of Man and Guernsey.

Figure 8: CoP, MoP, CoC and CMoP usage in primary THRs by year in Germany.

51 | 52

Published by CeramTec GmbH CeramTec-Platz 1–9 | 73207 Plochingen, Germany Phone: +49 7153 611-513 ceranews@ceramtec.de | www.ceranews.com Stuttgart district court commercial register, no. 734826 Stuttgart district court commercial register, no. 734826

Concept and Editing: Florence Petkow, Dr. Alessandro Alan Porporati Design and Production: Fiona Lennartz

CeramTec is committed to selecting and bringing to inter-ested parties relevant articles on bioceramics related topics. The presented authors' views and opinions are solely those of the authors of these publications. It is the focus and intent of CeraNews that CeramTec presents and comments on the authors' views and opinions in a specific context. Such comments and editorials therefore solely express CeramTec's views and opinions and not necessarily those of the quoted authors.

All statements are provided for educational purposes. For product, safety, and risk information, always refer to the labeling of the legal manufacturer.

Conventional femoral BIOLOX® *delta* heads and inserts as well as BIOLOX® OPTION products are registered by CeramTec's customers. Products are not registered / available in all

### **OUTCOMES RESEARCH | REGISTRIES ANNUAL REPORTS 2023 IN REVIEW**

Figure 9: CoP, MoP and CMoP usage in primary THRs by year in the United States.

Figure 10: CoP, MoP, CoC and CMoP usage in primary THRs by year in the Netherlands.

Figure 11: Annual use of dual mobility bearings in primary THRs in the NJR, AJRR, EPRD, and LROI.

Figure 12: The most common reasons for revision in England, Wales, Northern Ireland, the Isle of Man and Guernsey, Australia, the USA and the Netherlands.

Figure 13: Reasons for revision by year in Germany.

Figure 14: Reasons for revision by year in the Netherlands.

Figure 15: Reasons for revision by year in New Zealand.

Figure 16: Cumulative revision rates in primary hip replacement with Mop, CoP, and CoC bearings in combination with different fixation methods in England, Wales, Northern Ireland, the Isle of Man and Guernsey.

Figure 17: Cumulative revision rates in primary hip replacement with Resurfacing MoM and Resurfacing CoC in England, Wales, Northern Ireland, the Isle of Man and Guernsey.

Figure 18: Cumulative revision rates in primary THRs with CoXLPE, MoXLPE and CoC bearings (Primary Diagnosis OA) in Australia.

Figure 19: Cumulative revision rates of XLPE acetabulum in primary THRs by head size (Primary Diagnosis OA, restricted to modern prostheses).

Figure 20: Cumulative revision of mixed ceramic/mixed ceramic bearings (Primary Diagnosis OA, restricted to modern prostheses) by head size in Australia.

Figure 21: Cumulative revision rates of CohXLPE, CohXLPE+Antiox, CoC and MohXLPE in elective hip replacements by stem fixation in Germany.

Figure 22: Cumulative revision rates of different fixations in elective hip replacements in Germany.

Figure 23: Cumulative revision rates of head size in elective hip replacements with different fixations in Germany.

Figure 24: Cumulative major revisions of bearings in primary THRs in the Netherlands.

Figure 25: Cumulative revisions for dislocation by head sizes in the Netherlands.

Table 1: General information of national joint registries.

**Table 2:** Revision data by bearing type in New Zealand.

Table 3: Revision data by head size in New Zealand.

52 | 52

Published by CeramTec GmbH CeramTec-Platz 1–9 | 73207 Plochingen, Germany Phone: +49 7153 611-513 ceranews@ceramtec.de | www.ceranews.com Stuttgart district court commercial register, no. 734826 VAT identification no. DE814031115

Concept and Editing: Florence Petkow, Dr. Alessandro Alan Porporati Design and Production: Fiona Lennartz

CeramTec is committed to selecting and bringing to inter-ested parties relevant articles on bioceramics related topics. The presented authors' views and opinions are solely those of the authors of these publications. It is the focus and intent of CeraNews that CeramTec presents and comments on the authors' views and opinions in a specific context. Such comments and editorials therefore solely express CeramTec's views and opinions and not necessarily those of the quoted authors.

All statements are provided for educational purposes. For product, safety, and risk information, always refer to the labeling of the legal manufacturer.

Conventional femoral BIOLOX® delta heads and inserts as w as BIOLOX® OPTION products are registered by CeramTec's customers. Products are not registered / available in all

(in) 🖂 🌐